Plant-based Vaccine Market By Clinical Trial (Phase I, Phase II, Others); By Type (Bacterial/ Agrobacterial vaccines, Transgenic, Viral Vaccines, Fungal Vaccines, Recombinant subunit vaccines, Parasitic Vaccines, Others); By Source (Tobacco, potato, Maize, Nicotiana benthamiana, Carrot cells, tobacco cells, Strawberry, Rice, Lettuce, Spinach, Others); By Disease Indication (Enterotoxigenic E. coli, Ebola virus (SUDV, ZEBOV, Côte d’Ivoire ebolavirus, Bundibugyo ebolavirus), Norovirus, Hepatitis B virus, Rabies, Influenza (H1N1, H7N9, Others), Cholera, Respiratory Syndromes, Cancer, Others); By Mode of Administration (Intramuscular, Oral Administration, Others); By End Users (Hospitals, Clinics, Primary Care Centers, Others); By Region (U.S., Canada, Mexico, Rest of North America, France, UK, Spain, Germany, Italy, Nordic Countries , Benelux Union, Rest of Europe, China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Singapore, Philippines, Indonesia, Thailand, Malaysia, Vietnam, Rest of Southeast Asia), Brazil, Argentina, Rest of Latin America, Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa) – Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2020 - 2028
Industry Trends
The industries spanning across various countries decide the level of development occurring in these areas. Healthcare is a sector that is observed to have an impact across various industry verticals be it in the positive or negative sense. Improvements in the healthcare sector have been influential in the growth of other industries operating across the world. But, in times wherein diseases become an outbreak and lead to limited control in the sector, industries are affected in an adverse fashion. This has led medical researchers to be on their toes with development initiatives for curative and preventive measures for mitigating the risks of various diseases. Vaccination has been seen to be a notable component of the preventive care measures undertaken from the healthcare sector for curbing the spread of numerous diseases and disorders. The concept of vaccination was observed to originate through the works of Edward Jenner in the 1700s. Jenner was working on creating a care solution for the disease of smallpox. Edward Jenner was also instrumental in the development of the name ‘vaccine’ for the products. Louis Pasteur later became a notable contributor for the development of vaccines in later years. Vaccines are considered to be in one of four forms, whole celled killed formulations, whole celled live attenuated formulations, conjugate vaccines and subunit vaccines. Depending on the type of the disease that is being studied for, the form of the vaccine is decided in order to provide with the patient with an optimal care and recovery phase. Advancements in vaccine technology have led to a growth in the development and production abilities for vaccine manufacturers on the global scale. In recent years, the focus of research organizations has gone from traditional vaccine development processes to finding alternative ways for the development of vaccines. Plants are seen to be one of the notable alternative bases used for the development of vaccines. The advantages of plant-based vaccine as compared to traditional vaccine forms including lack of reverse virulence, easier transportation, and production processes, among others. These factors are seen to benefit the market in recent years and would be beneficial for the future growth of the market. Global plant-based vaccine market is expected to grow at a CAGR of 23.8% over the forecast period.
By Clinical Trial
Plant-based vaccines are seen to be a relatively newer addition to the healthcare sector. This has led to a limited commercialization of the products in the market. The higher percentage of products in the market is observed to be currently in clinical trial stages. The growing prevalence of the novel coronavirus has also resulted in the development of plant-based vaccines across numerous countries. These conditions have provided the market with a positive outlook for the future in terms of growth.
By Type
Plant based vaccines are seen to be notably in the form of recombinant vaccines owing to the capability of the type to work like natural infections against the immune systems of the patients. This helps in creation of vaccines in an easier manner as compared to other types and leads to an improvement in speed with respect to the path from research to production and distribution. Furthermore, the development of bacterial/agrobacterial vaccines and viral vaccines has been observed to grow over the years. These vaccines utilize bacteria and viruses as an ingredient in order to work with the immune system for improving the response of the patient’s body against the disorder. The recent initiatives for the development of plant-based vaccine for the novel coronavirus have included the recombinant vaccine types with proteins as the notable base for the key ingredients. These initiatives from companies related to the adoption of plant bases for various diseases in a proactive fashion are providing the market with a positive outlook for the growth in the near future.
By Source
The effectiveness of plant-based vaccine is seen to be dependent on the plant which is used as the source for the development. Notable plant sources for the vaccines include tobacco, maize, and carrot cells, among others. The application of these sources has been seen to cover a wide range of disorders. Researchers have been studying various plant forms to look for potential sources related to vaccine development. These conditions are expected to play a key role in the growth of the market.
By Disease Indication
The market has been helped with the growing investments from research organizations towards development initiatives related to vaccines. Vaccines are observed to provide preventive care to patients and hence, have become a notable addition to the healthcare portfolio in working against a wide range of diseases. The rising prevalence of diseases across various regions has led to improvements in development initiatives for vaccines based on plant sources. Viral disorders have been observed to grow in prevalence over the recent decade. The incidence of Ebola and the novel coronavirus has been instrumental in increasing the importance of plant bases related to the development of vaccines. This factor has led to an increased development of plant-based vaccines that can tackle viral diseases and help in reducing the strain of these disorders on the healthcare sector.
By Region
The ventures related to plant-based vaccine is observed to be widespread in the global perspective. Concerns related to human loss and the financial loss related to the outbreak of any disease has led the healthcare sector across various regions to be proactive in testing times. Vaccine development has now grown from a niche field for research to one of the most promising areas in healthcare. North America has been a key proponent of this trend as a result. Numerous organizations hailing from the countries in the region have been venturing into the sector and are working towards the development of plant-based vaccines for human and animal care. Companies such as Medicago, and Creative Biolabs have been notable contributors for improving the conditions of plant based vaccines in the region and are providing the market with an impetus for growth. The initiatives of the companies over the years have been helpful for the growth in market revenue among the countries in the region. Another region which is expected to play a key role in the progress of the market is observed to be Asia Pacific. The region is seen to be home to numerous organizations operating in the healthcare sector. These organizations include companies that are based in the region along with the international ventures from companies based out of other regions. The investments from these companies in terms of efforts and the monetary forms have been helpful for the growth of the healthcare sector as a whole. Plant-based vaccine has become a notable investment area for the companies in the region and has resulted in the development of plant-based vaccine related to the ongoing healthcare efforts against the novel coronavirus. Organizations including Baiya Phytopharm Co., Ltd. and iBio Inc. among others have been crucial for the development process in the region. These factors are expected to provide the market a foundation for growth and are aimed to play a vital role in the rate of growth achieved by the market over the forecast period.
Plant-based Vaccine Market Revenue & Forecast, (US$ Million), 2015 – 2028
Competitive Landscape
The report provides both, qualitative and quantitative research of plant-based vaccine market, as well as provides comprehensive insights and development methods adopted by the key contenders. The plant-based vaccine report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analysed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.
Some of the players operating in the plant-based vaccine market are, Creative Biolabs, iBio, Inc., Medicago Inc., and Nomad Bioscience GmbH (Icon Genetics GmbH) amongst.
Plant-based Vaccine Market:
- By Clinical Trial
- Phase I
- Phase II
- Others
- By Type
- Bacterial/ Agrobacterial vaccines
- Transgenic
- Viral Vaccines
- Fungal Vaccines
- Recombinant subunit vaccines
- Parasitic Vaccines
- Others
- By Source
- Tobacco, potato
- Maize
- Nicotiana benthamiana
- Carrot cells, tobacco cells
- Strawberry
- Rice
- Lettuce
- Spinach
- Others
- By Disease Indication
- Enterotoxigenic E. coli
- Ebola virus
- SUDV
- ZEBOV
- Côte d’Ivoire ebolavirus
- Bundibugyo ebolavirus
- Norovirus
- Hepatitis B virus
- Rabies
- Influenza
- H1N1
- H5N1
- H7N9
- Others
- Cholera
- Respiratory Syndromes
- Cancer
- Others
- By Mode of Administration
- Intramuscular
- Oral Administration
- Others
- By End Users
- Hospitals
- Clinics
- Primary Care Centers
- Others
- By Region:
- North America
- U.S.
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
- North America
Table of Contents
1. Market Scope
1.1. Market
Segmentation
1.2. Years
Considered
1.2.1. Historic
Years: 2015 - 2018
1.2.2. Base
Year: 2019
1.2.3. Forecast
Years: 2020 – 2028
2. Key Target Audiences
3. Research Methodology
3.1. Primary
Research
3.1.1. Research
Questionnaire
3.1.2. Global
Percentage Breakdown
3.1.3. Primary
Interviews: Key Opinion Leaders (KOLs)
3.2. Secondary
Research
3.2.1. Paid
Databases
3.2.2. Secondary
Sources
3.3. Market
Size Estimates
3.3.1. Top-Down
Approach
3.3.2. Bottom-Up
Approach
3.4. Data
Triangulation Methodology
3.5. Research
Assumptions
4. Recommendations and Insights from AMI’s Perspective**
5. Holistic Overview of Plant-based Vaccines Market
6. Market Synopsis:
Plant-based Vaccines Market
7. Plant-based Vaccines Market Analysis: Qualitative Perspective
7.1. Introduction
7.1.1. Product
Definition
7.1.2. Industry
Development
7.2. Market
Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.3. Trends in
Plant-based Vaccines Market
7.4. Market
Determinants Radar Chart
7.5. Macro-Economic
and Micro-Economic Indicators: Plant-based Vaccines Market
7.6. Porter’s Five Force Analysis
7.7. Impact of
Covid-19 on Plant-based Vaccines Market
8. Global Plant-based Vaccines Market Analysis and Forecasts,
2020 – 2028
8.1. Overview
8.1.1. Global
Plant-based Vaccines Market Revenue (US$ Mn)
8.2. Global
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Clinical Trial
8.2.1. Phase I
8.2.1.1. Definition
8.2.1.2. Market
Estimation and Penetration, 2015 – 2019
8.2.1.3. Market
Forecast, 2020 – 2028
8.2.1.4. Compound
Annual Growth Rate (CAGR)
8.2.1.5. Regional
Bifurcation
8.2.1.5.1. North
America
8.2.1.5.1.1. Market
Estimation, 2015 – 2019
8.2.1.5.1.2. Market
Forecast, 2020 – 2028
8.2.1.5.2. Europe
8.2.1.5.2.1. Market
Estimation, 2015 – 2019
8.2.1.5.2.2. Market
Forecast, 2020 – 2028
8.2.1.5.3. Asia
Pacific
8.2.1.5.3.1. Market
Estimation, 2015 – 2019
8.2.1.5.3.2. Market
Forecast, 2020 – 2028
8.2.1.5.4. Middle
East and Africa
8.2.1.5.4.1. Market
Estimation, 2015 – 2019
8.2.1.5.4.2. Market
Forecast, 2020 – 2028
8.2.1.5.5. Latin
America
8.2.1.5.5.1. Market
Estimation, 2015 – 2019
8.2.1.5.5.2. Market
Forecast, 2020 – 2028
8.2.2. Phase II
8.2.2.1. Definition
8.2.2.2. Market
Estimation and Penetration, 2015 – 2019
8.2.2.3. Market
Forecast, 2020 – 2028
8.2.2.4. Compound
Annual Growth Rate (CAGR)
8.2.2.5. Regional
Bifurcation
8.2.2.5.1. North
America
8.2.2.5.1.1. Market
Estimation, 2015 – 2019
8.2.2.5.1.2. Market
Forecast, 2020 – 2028
8.2.2.5.2. Europe
8.2.2.5.2.1. Market
Estimation, 2015 – 2019
8.2.2.5.2.2. Market
Forecast, 2020 – 2028
8.2.2.5.3. Asia
Pacific
8.2.2.5.3.1. Market
Estimation, 2015 – 2019
8.2.2.5.3.2. Market
Forecast, 2020 – 2028
8.2.2.5.4. Middle
East and Africa
8.2.2.5.4.1. Market
Estimation, 2015 – 2019
8.2.2.5.4.2. Market
Forecast, 2020 – 2028
8.2.2.5.5. Latin
America
8.2.2.5.5.1. Market
Estimation, 2015 – 2019
8.2.2.5.5.2. Market
Forecast, 2020 – 2028
8.2.3. Others
8.2.3.1. Definition
8.2.3.2. Market
Estimation and Penetration, 2015 – 2019
8.2.3.3. Market
Forecast, 2020 – 2028
8.2.3.4. Compound
Annual Growth Rate (CAGR)
8.2.3.5. Regional
Bifurcation
8.2.3.5.1. North
America
8.2.3.5.1.1. Market
Estimation, 2015 – 2019
8.2.3.5.1.2. Market
Forecast, 2020 – 2028
8.2.3.5.2. Europe
8.2.3.5.2.1. Market
Estimation, 2015 – 2019
8.2.3.5.2.2. Market
Forecast, 2020 – 2028
8.2.3.5.3. Asia
Pacific
8.2.3.5.3.1. Market
Estimation, 2015 – 2019
8.2.3.5.3.2. Market
Forecast, 2020 – 2028
8.2.3.5.4. Middle
East and Africa
8.2.3.5.4.1. Market
Estimation, 2015 – 2019
8.2.3.5.4.2. Market
Forecast, 2020 – 2028
8.2.3.5.5. Latin
America
8.2.3.5.5.1. Market
Estimation, 2015 – 2019
8.2.3.5.5.2. Market
Forecast, 2020 – 2028
8.3. Key
Segment for Channeling Investments
8.3.1. By
Clinical Trial
9. Global Plant-based Vaccines Market Analysis and Forecasts,
2020 – 2028
9.1. Overview
9.2. Global
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Type
9.2.1. Bacterial/
Agrobacterial vaccines
9.2.1.1. Definition
9.2.1.2. Market
Estimation and Penetration, 2015 – 2019
9.2.1.3. Market
Forecast, 2020 – 2028
9.2.1.4. Compound
Annual Growth Rate (CAGR)
9.2.1.5. Regional
Bifurcation
9.2.1.5.1. North
America
9.2.1.5.1.1. Market
Estimation, 2015 – 2019
9.2.1.5.1.2. Market
Forecast, 2020 – 2028
9.2.1.5.2. Europe
9.2.1.5.2.1. Market
Estimation, 2015 – 2019
9.2.1.5.2.2. Market
Forecast, 2020 – 2028
9.2.1.5.3. Asia
Pacific
9.2.1.5.3.1. Market
Estimation, 2015 – 2019
9.2.1.5.3.2. Market
Forecast, 2020 – 2028
9.2.1.5.4. Middle
East and Africa
9.2.1.5.4.1. Market
Estimation, 2015 – 2019
9.2.1.5.4.2. Market
Forecast, 2020 – 2028
9.2.1.5.5. Latin
America
9.2.1.5.5.1. Market
Estimation, 2015 – 2019
9.2.1.5.5.2. Market
Forecast, 2020 – 2028
9.2.2. Transgenic
9.2.2.1. Definition
9.2.2.2. Market
Estimation and Penetration, 2015 – 2019
9.2.2.3. Market
Forecast, 2020 – 2028
9.2.2.4. Compound
Annual Growth Rate (CAGR)
9.2.2.5. Regional
Bifurcation
9.2.2.5.1. North
America
9.2.2.5.1.1. Market
Estimation, 2015 – 2019
9.2.2.5.1.2. Market
Forecast, 2020 – 2028
9.2.2.5.2. Europe
9.2.2.5.2.1. Market
Estimation, 2015 – 2019
9.2.2.5.2.2. Market
Forecast, 2020 – 2028
9.2.2.5.3. Asia
Pacific
9.2.2.5.3.1. Market
Estimation, 2015 – 2019
9.2.2.5.3.2. Market
Forecast, 2020 – 2028
9.2.2.5.4. Middle
East and Africa
9.2.2.5.4.1. Market
Estimation, 2015 – 2019
9.2.2.5.4.2. Market
Forecast, 2020 – 2028
9.2.2.5.5. Latin
America
9.2.2.5.5.1. Market
Estimation, 2015 – 2019
9.2.2.5.5.2. Market
Forecast, 2020 – 2028
9.2.3. Viral
Vaccines
9.2.3.1. Definition
9.2.3.2. Market
Estimation and Penetration, 2015 – 2019
9.2.3.3. Market
Forecast, 2020 – 2028
9.2.3.4. Compound
Annual Growth Rate (CAGR)
9.2.3.5. Regional
Bifurcation
9.2.3.5.1. North
America
9.2.3.5.1.1. Market
Estimation, 2015 – 2019
9.2.3.5.1.2. Market
Forecast, 2020 – 2028
9.2.3.5.2. Europe
9.2.3.5.2.1. Market
Estimation, 2015 – 2019
9.2.3.5.2.2. Market
Forecast, 2020 – 2028
9.2.3.5.3. Asia
Pacific
9.2.3.5.3.1. Market
Estimation, 2015 – 2019
9.2.3.5.3.2. Market
Forecast, 2020 – 2028
9.2.3.5.4. Middle
East and Africa
9.2.3.5.4.1. Market
Estimation, 2015 – 2019
9.2.3.5.4.2. Market
Forecast, 2020 – 2028
9.2.3.5.5. Latin
America
9.2.3.5.5.1. Market
Estimation, 2015 – 2019
9.2.3.5.5.2. Market
Forecast, 2020 – 2028
9.2.4. Fungal
Vaccines
9.2.4.1. Definition
9.2.4.2. Market
Estimation and Penetration, 2015 – 2019
9.2.4.3. Market
Forecast, 2020 – 2028
9.2.4.4. Compound
Annual Growth Rate (CAGR)
9.2.4.5. Regional
Bifurcation
9.2.4.5.1. North
America
9.2.4.5.1.1. Market
Estimation, 2015 – 2019
9.2.4.5.1.2. Market
Forecast, 2020 – 2028
9.2.4.5.2. Europe
9.2.4.5.2.1. Market
Estimation, 2015 – 2019
9.2.4.5.2.2. Market
Forecast, 2020 – 2028
9.2.4.5.3. Asia
Pacific
9.2.4.5.3.1. Market
Estimation, 2015 – 2019
9.2.4.5.3.2. Market
Forecast, 2020 – 2028
9.2.4.5.4. Middle
East and Africa
9.2.4.5.4.1. Market
Estimation, 2015 – 2019
9.2.4.5.4.2. Market
Forecast, 2020 – 2028
9.2.4.5.5. Latin
America
9.2.4.5.5.1. Market
Estimation, 2015 – 2019
9.2.4.5.5.2. Market
Forecast, 2020 – 2028
9.2.5. Recombinant
subunit vaccines
9.2.5.1. Definition
9.2.5.2. Market
Estimation and Penetration, 2015 – 2019
9.2.5.3. Market
Forecast, 2020 – 2028
9.2.5.4. Compound
Annual Growth Rate (CAGR)
9.2.5.5. Regional
Bifurcation
9.2.5.5.1. North
America
9.2.5.5.1.1. Market
Estimation, 2015 – 2019
9.2.5.5.1.2. Market
Forecast, 2020 – 2028
9.2.5.5.2. Europe
9.2.5.5.2.1. Market
Estimation, 2015 – 2019
9.2.5.5.2.2. Market
Forecast, 2020 – 2028
9.2.5.5.3. Asia
Pacific
9.2.5.5.3.1. Market
Estimation, 2015 – 2019
9.2.5.5.3.2. Market
Forecast, 2020 – 2028
9.2.5.5.4. Middle
East and Africa
9.2.5.5.4.1. Market
Estimation, 2015 – 2019
9.2.5.5.4.2. Market
Forecast, 2020 – 2028
9.2.5.5.5. Latin
America
9.2.5.5.5.1. Market
Estimation, 2015 – 2019
9.2.5.5.5.2. Market
Forecast, 2020 – 2028
9.2.6. Parasitic
Vaccines
9.2.6.1. Definition
9.2.6.2. Market
Estimation and Penetration, 2015 – 2019
9.2.6.3. Market
Forecast, 2020 – 2028
9.2.6.4. Compound
Annual Growth Rate (CAGR)
9.2.6.5. Regional
Bifurcation
9.2.6.5.1. North
America
9.2.6.5.1.1. Market
Estimation, 2015 – 2019
9.2.6.5.1.2. Market
Forecast, 2020 – 2028
9.2.6.5.2. Europe
9.2.6.5.2.1. Market
Estimation, 2015 – 2019
9.2.6.5.2.2. Market
Forecast, 2020 – 2028
9.2.6.5.3. Asia
Pacific
9.2.6.5.3.1. Market
Estimation, 2015 – 2019
9.2.6.5.3.2. Market
Forecast, 2020 – 2028
9.2.6.5.4. Middle
East and Africa
9.2.6.5.4.1. Market
Estimation, 2015 – 2019
9.2.6.5.4.2. Market
Forecast, 2020 – 2028
9.2.6.5.5. Latin
America
9.2.6.5.5.1. Market
Estimation, 2015 – 2019
9.2.6.5.5.2. Market
Forecast, 2020 – 2028
9.2.7. Others
9.2.7.1. Definition
9.2.7.2. Market
Estimation and Penetration, 2015 – 2019
9.2.7.3. Market
Forecast, 2020 – 2028
9.2.7.4. Compound
Annual Growth Rate (CAGR)
9.2.7.5. Regional
Bifurcation
9.2.7.5.1. North
America
9.2.7.5.1.1. Market
Estimation, 2015 – 2019
9.2.7.5.1.2. Market
Forecast, 2020 – 2028
9.2.7.5.2. Europe
9.2.7.5.2.1. Market
Estimation, 2015 – 2019
9.2.7.5.2.2. Market
Forecast, 2020 – 2028
9.2.7.5.3. Asia
Pacific
9.2.7.5.3.1. Market
Estimation, 2015 – 2019
9.2.7.5.3.2. Market
Forecast, 2020 – 2028
9.2.7.5.4. Middle
East and Africa
9.2.7.5.4.1. Market
Estimation, 2015 – 2019
9.2.7.5.4.2. Market
Forecast, 2020 – 2028
9.2.7.5.5. Latin
America
9.2.7.5.5.1. Market
Estimation, 2015 – 2019
9.2.7.5.5.2. Market
Forecast, 2020 – 2028
9.3. Key
Segment for Channeling Investments
9.3.1. By Type
10. Global Plant-based Vaccines Market Analysis and Forecasts,
2020 – 2028
10.1. Overview
10.2. Global
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Source
10.2.1. Tobacco,
potato
10.2.1.1. Definition
10.2.1.2. Market
Estimation and Penetration, 2015 – 2019
10.2.1.3. Market
Forecast, 2020 – 2028
10.2.1.4. Compound
Annual Growth Rate (CAGR)
10.2.1.5. Regional
Bifurcation
10.2.1.5.1. North
America
10.2.1.5.1.1. Market
Estimation, 2015 – 2019
10.2.1.5.1.2. Market
Forecast, 2020 – 2028
10.2.1.5.2. Europe
10.2.1.5.2.1. Market
Estimation, 2015 – 2019
10.2.1.5.2.2. Market
Forecast, 2020 – 2028
10.2.1.5.3. Asia
Pacific
10.2.1.5.3.1. Market
Estimation, 2015 – 2019
10.2.1.5.3.2. Market
Forecast, 2020 – 2028
10.2.1.5.4. Middle
East and Africa
10.2.1.5.4.1. Market
Estimation, 2015 – 2019
10.2.1.5.4.2. Market
Forecast, 2020 – 2028
10.2.1.5.5. Latin
America
10.2.1.5.5.1. Market
Estimation, 2015 – 2019
10.2.1.5.5.2. Market
Forecast, 2020 – 2028
10.2.2. Maize
10.2.2.1. Definition
10.2.2.2. Market
Estimation and Penetration, 2015 – 2019
10.2.2.3. Market
Forecast, 2020 – 2028
10.2.2.4. Compound
Annual Growth Rate (CAGR)
10.2.2.5. Regional
Bifurcation
10.2.2.5.1. North
America
10.2.2.5.1.1. Market
Estimation, 2015 – 2019
10.2.2.5.1.2. Market
Forecast, 2020 – 2028
10.2.2.5.2. Europe
10.2.2.5.2.1. Market
Estimation, 2015 – 2019
10.2.2.5.2.2. Market
Forecast, 2020 – 2028
10.2.2.5.3. Asia
Pacific
10.2.2.5.3.1. Market
Estimation, 2015 – 2019
10.2.2.5.3.2. Market
Forecast, 2020 – 2028
10.2.2.5.4. Middle
East and Africa
10.2.2.5.4.1. Market
Estimation, 2015 – 2019
10.2.2.5.4.2. Market
Forecast, 2020 – 2028
10.2.2.5.5. Latin
America
10.2.2.5.5.1. Market
Estimation, 2015 – 2019
10.2.2.5.5.2. Market
Forecast, 2020 – 2028
10.2.3. Nicotiana
benthamiana
10.2.3.1. Definition
10.2.3.2. Market
Estimation and Penetration, 2015 – 2019
10.2.3.3. Market
Forecast, 2020 – 2028
10.2.3.4. Compound
Annual Growth Rate (CAGR)
10.2.3.5. Regional
Bifurcation
10.2.3.5.1. North
America
10.2.3.5.1.1. Market
Estimation, 2015 – 2019
10.2.3.5.1.2. Market
Forecast, 2020 – 2028
10.2.3.5.2. Europe
10.2.3.5.2.1. Market
Estimation, 2015 – 2019
10.2.3.5.2.2. Market
Forecast, 2020 – 2028
10.2.3.5.3. Asia
Pacific
10.2.3.5.3.1. Market
Estimation, 2015 – 2019
10.2.3.5.3.2. Market
Forecast, 2020 – 2028
10.2.3.5.4. Middle
East and Africa
10.2.3.5.4.1. Market
Estimation, 2015 – 2019
10.2.3.5.4.2. Market
Forecast, 2020 – 2028
10.2.3.5.5. Latin
America
10.2.3.5.5.1. Market
Estimation, 2015 – 2019
10.2.3.5.5.2. Market
Forecast, 2020 – 2028
10.2.4. Carrot
cells, tobacco cells
10.2.4.1. Definition
10.2.4.2. Market
Estimation and Penetration, 2015 – 2019
10.2.4.3. Market
Forecast, 2020 – 2028
10.2.4.4. Compound
Annual Growth Rate (CAGR)
10.2.4.5. Regional
Bifurcation
10.2.4.5.1. North
America
10.2.4.5.1.1. Market
Estimation, 2015 – 2019
10.2.4.5.1.2. Market
Forecast, 2020 – 2028
10.2.4.5.2. Europe
10.2.4.5.2.1. Market
Estimation, 2015 – 2019
10.2.4.5.2.2. Market
Forecast, 2020 – 2028
10.2.4.5.3. Asia
Pacific
10.2.4.5.3.1. Market
Estimation, 2015 – 2019
10.2.4.5.3.2. Market
Forecast, 2020 – 2028
10.2.4.5.4. Middle
East and Africa
10.2.4.5.4.1. Market
Estimation, 2015 – 2019
10.2.4.5.4.2. Market
Forecast, 2020 – 2028
10.2.4.5.5. Latin
America
10.2.4.5.5.1. Market
Estimation, 2015 – 2019
10.2.4.5.5.2. Market
Forecast, 2020 – 2028
10.2.5. Strawberry
10.2.5.1. Definition
10.2.5.2. Market
Estimation and Penetration, 2015 – 2019
10.2.5.3. Market
Forecast, 2020 – 2028
10.2.5.4. Compound
Annual Growth Rate (CAGR)
10.2.5.5. Regional
Bifurcation
10.2.5.5.1. North
America
10.2.5.5.1.1. Market
Estimation, 2015 – 2019
10.2.5.5.1.2. Market
Forecast, 2020 – 2028
10.2.5.5.2. Europe
10.2.5.5.2.1. Market
Estimation, 2015 – 2019
10.2.5.5.2.2. Market
Forecast, 2020 – 2028
10.2.5.5.3. Asia
Pacific
10.2.5.5.3.1. Market
Estimation, 2015 – 2019
10.2.5.5.3.2. Market
Forecast, 2020 – 2028
10.2.5.5.4. Middle
East and Africa
10.2.5.5.4.1. Market
Estimation, 2015 – 2019
10.2.5.5.4.2. Market
Forecast, 2020 – 2028
10.2.5.5.5. Latin
America
10.2.5.5.5.1. Market
Estimation, 2015 – 2019
10.2.5.5.5.2. Market
Forecast, 2020 – 2028
10.2.6. Rice
10.2.6.1. Definition
10.2.6.2. Market
Estimation and Penetration, 2015 – 2019
10.2.6.3. Market
Forecast, 2020 – 2028
10.2.6.4. Compound
Annual Growth Rate (CAGR)
10.2.6.5. Regional
Bifurcation
10.2.6.5.1. North
America
10.2.6.5.1.1. Market
Estimation, 2015 – 2019
10.2.6.5.1.2. Market
Forecast, 2020 – 2028
10.2.6.5.2. Europe
10.2.6.5.2.1. Market
Estimation, 2015 – 2019
10.2.6.5.2.2. Market
Forecast, 2020 – 2028
10.2.6.5.3. Asia
Pacific
10.2.6.5.3.1. Market
Estimation, 2015 – 2019
10.2.6.5.3.2. Market
Forecast, 2020 – 2028
10.2.6.5.4. Middle
East and Africa
10.2.6.5.4.1. Market
Estimation, 2015 – 2019
10.2.6.5.4.2. Market
Forecast, 2020 – 2028
10.2.6.5.5. Latin
America
10.2.6.5.5.1. Market
Estimation, 2015 – 2019
10.2.6.5.5.2. Market
Forecast, 2020 – 2028
10.2.7. Lettuce
10.2.7.1. Definition
10.2.7.2. Market
Estimation and Penetration, 2015 – 2019
10.2.7.3. Market
Forecast, 2020 – 2028
10.2.7.4. Compound
Annual Growth Rate (CAGR)
10.2.7.5. Regional
Bifurcation
10.2.7.5.1. North
America
10.2.7.5.1.1. Market
Estimation, 2015 – 2019
10.2.7.5.1.2. Market
Forecast, 2020 – 2028
10.2.7.5.2. Europe
10.2.7.5.2.1. Market
Estimation, 2015 – 2019
10.2.7.5.2.2. Market
Forecast, 2020 – 2028
10.2.7.5.3. Asia
Pacific
10.2.7.5.3.1. Market
Estimation, 2015 – 2019
10.2.7.5.3.2. Market
Forecast, 2020 – 2028
10.2.7.5.4. Middle
East and Africa
10.2.7.5.4.1. Market
Estimation, 2015 – 2019
10.2.7.5.4.2. Market
Forecast, 2020 – 2028
10.2.7.5.5. Latin
America
10.2.7.5.5.1. Market
Estimation, 2015 – 2019
10.2.7.5.5.2. Market
Forecast, 2020 – 2028
10.2.8. Spinach
10.2.8.1. Definition
10.2.8.2. Market
Estimation and Penetration, 2015 – 2019
10.2.8.3. Market
Forecast, 2020 – 2028
10.2.8.4. Compound
Annual Growth Rate (CAGR)
10.2.8.5. Regional
Bifurcation
10.2.8.5.1. North
America
10.2.8.5.1.1. Market
Estimation, 2015 – 2019
10.2.8.5.1.2. Market
Forecast, 2020 – 2028
10.2.8.5.2. Europe
10.2.8.5.2.1. Market
Estimation, 2015 – 2019
10.2.8.5.2.2. Market
Forecast, 2020 – 2028
10.2.8.5.3. Asia
Pacific
10.2.8.5.3.1. Market
Estimation, 2015 – 2019
10.2.8.5.3.2. Market
Forecast, 2020 – 2028
10.2.8.5.4. Middle
East and Africa
10.2.8.5.4.1. Market
Estimation, 2015 – 2019
10.2.8.5.4.2. Market
Forecast, 2020 – 2028
10.2.8.5.5. Latin
America
10.2.8.5.5.1. Market
Estimation, 2015 – 2019
10.2.8.5.5.2. Market
Forecast, 2020 – 2028
10.2.9. Others
10.2.9.1. Definition
10.2.9.2. Market
Estimation and Penetration, 2015 – 2019
10.2.9.3. Market
Forecast, 2020 – 2028
10.2.9.4. Compound
Annual Growth Rate (CAGR)
10.2.9.5. Regional
Bifurcation
10.2.9.5.1. North
America
10.2.9.5.1.1. Market
Estimation, 2015 – 2019
10.2.9.5.1.2. Market
Forecast, 2020 – 2028
10.2.9.5.2. Europe
10.2.9.5.2.1. Market
Estimation, 2015 – 2019
10.2.9.5.2.2. Market
Forecast, 2020 – 2028
10.2.9.5.3. Asia
Pacific
10.2.9.5.3.1. Market
Estimation, 2015 – 2019
10.2.9.5.3.2. Market
Forecast, 2020 – 2028
10.2.9.5.4. Middle
East and Africa
10.2.9.5.4.1. Market
Estimation, 2015 – 2019
10.2.9.5.4.2. Market
Forecast, 2020 – 2028
10.2.9.5.5. Latin
America
10.2.9.5.5.1. Market
Estimation, 2015 – 2019
10.2.9.5.5.2. Market
Forecast, 2020 – 2028
10.3. Key
Segment for Channeling Investments
10.3.1. By
Source
11. Global Plant-based Vaccines Market Analysis and Forecasts,
2020 – 2028
11.1. Overview
11.2. Global
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Disease Indication
11.2.1. Enterotoxigenic
E. coli
11.2.1.1. Definition
11.2.1.2. Market
Estimation and Penetration, 2015 – 2019
11.2.1.3. Market
Forecast, 2020 – 2028
11.2.1.4. Compound
Annual Growth Rate (CAGR)
11.2.1.5. Regional
Bifurcation
11.2.1.5.1. North
America
11.2.1.5.1.1. Market
Estimation, 2015 – 2019
11.2.1.5.1.2. Market
Forecast, 2020 – 2028
11.2.1.5.2. Europe
11.2.1.5.2.1. Market
Estimation, 2015 – 2019
11.2.1.5.2.2. Market
Forecast, 2020 – 2028
11.2.1.5.3. Asia
Pacific
11.2.1.5.3.1. Market
Estimation, 2015 – 2019
11.2.1.5.3.2. Market
Forecast, 2020 – 2028
11.2.1.5.4. Middle
East and Africa
11.2.1.5.4.1. Market
Estimation, 2015 – 2019
11.2.1.5.4.2. Market
Forecast, 2020 – 2028
11.2.1.5.5. Latin
America
11.2.1.5.5.1. Market
Estimation, 2015 – 2019
11.2.1.5.5.2. Market
Forecast, 2020 – 2028
11.2.2. Ebola
virus (Definition, Market Estimation and Penetration, 2015 – 2019, Market
Estimation (2015 – 2019), Market Forecast (2020 – 2028), Compound Annual Growth
Rate (CAGR), Regional Bifurcation (North America, Europe, Asia Pacific, Middle
East and Africa, Latin America) and Information on SUDV, ZEBOV, Côte d’Ivoire
ebolavirus, Bundibugyo ebolavirus)
11.2.2.1. SUDV
11.2.2.2. ZEBOV
11.2.2.3. Côte
d’Ivoire ebolavirus
11.2.2.4. Bundibugyo
ebolavirus
11.2.3. Norovirus
11.2.3.1. Definition
11.2.3.2. Market
Estimation and Penetration, 2015 – 2019
11.2.3.3. Market
Forecast, 2020 – 2028
11.2.3.4. Compound
Annual Growth Rate (CAGR)
11.2.3.5. Regional
Bifurcation
11.2.3.5.1. North
America
11.2.3.5.1.1. Market
Estimation, 2015 – 2019
11.2.3.5.1.2. Market
Forecast, 2020 – 2028
11.2.3.5.2. Europe
11.2.3.5.2.1. Market
Estimation, 2015 – 2019
11.2.3.5.2.2. Market
Forecast, 2020 – 2028
11.2.3.5.3. Asia
Pacific
11.2.3.5.3.1. Market
Estimation, 2015 – 2019
11.2.3.5.3.2. Market
Forecast, 2020 – 2028
11.2.3.5.4. Middle
East and Africa
11.2.3.5.4.1. Market
Estimation, 2015 – 2019
11.2.3.5.4.2. Market
Forecast, 2020 – 2028
11.2.3.5.5. Latin
America
11.2.3.5.5.1. Market
Estimation, 2015 – 2019
11.2.3.5.5.2. Market
Forecast, 2020 – 2028
11.2.4. Hepatitis
B virus
11.2.4.1. Definition
11.2.4.2. Market
Estimation and Penetration, 2015 – 2019
11.2.4.3. Market
Forecast, 2020 – 2028
11.2.4.4. Compound
Annual Growth Rate (CAGR)
11.2.4.5. Regional
Bifurcation
11.2.4.5.1. North
America
11.2.4.5.1.1. Market
Estimation, 2015 – 2019
11.2.4.5.1.2. Market
Forecast, 2020 – 2028
11.2.4.5.2. Europe
11.2.4.5.2.1. Market
Estimation, 2015 – 2019
11.2.4.5.2.2. Market
Forecast, 2020 – 2028
11.2.4.5.3. Asia
Pacific
11.2.4.5.3.1. Market
Estimation, 2015 – 2019
11.2.4.5.3.2. Market
Forecast, 2020 – 2028
11.2.4.5.4. Middle
East and Africa
11.2.4.5.4.1. Market
Estimation, 2015 – 2019
11.2.4.5.4.2. Market
Forecast, 2020 – 2028
11.2.4.5.5. Latin
America
11.2.4.5.5.1. Market
Estimation, 2015 – 2019
11.2.4.5.5.2. Market
Forecast, 2020 – 2028
11.2.5. Rabies
11.2.5.1. Definition
11.2.5.2. Market
Estimation and Penetration, 2015 – 2019
11.2.5.3. Market
Forecast, 2020 – 2028
11.2.5.4. Compound
Annual Growth Rate (CAGR)
11.2.5.5. Regional
Bifurcation
11.2.5.5.1. North
America
11.2.5.5.1.1. Market
Estimation, 2015 – 2019
11.2.5.5.1.2. Market
Forecast, 2020 – 2028
11.2.5.5.2. Europe
11.2.5.5.2.1. Market
Estimation, 2015 – 2019
11.2.5.5.2.2. Market
Forecast, 2020 – 2028
11.2.5.5.3. Asia
Pacific
11.2.5.5.3.1. Market
Estimation, 2015 – 2019
11.2.5.5.3.2. Market
Forecast, 2020 – 2028
11.2.5.5.4. Middle
East and Africa
11.2.5.5.4.1. Market
Estimation, 2015 – 2019
11.2.5.5.4.2. Market
Forecast, 2020 – 2028
11.2.5.5.5. Latin
America
11.2.5.5.5.1. Market
Estimation, 2015 – 2019
11.2.5.5.5.2. Market
Forecast, 2020 – 2028
11.2.6. Influenza
(Definition, Market Estimation and Penetration, 2015 – 2019, Market Estimation
(2015 – 2019), Market Forecast (2020 – 2028), Compound Annual Growth Rate
(CAGR), Regional Bifurcation (North America, Europe, Asia Pacific, Middle East
and Africa, Latin America) and Information on H1N1, H5N1, H7N9, Others)
11.2.6.1. H1N1
11.2.6.2. H5N1
11.2.6.3. H7N9
11.2.6.4. Others
11.2.7. Cholera
11.2.7.1. Definition
11.2.7.2. Market
Estimation and Penetration, 2015 – 2019
11.2.7.3. Market
Forecast, 2020 – 2028
11.2.7.4. Compound
Annual Growth Rate (CAGR)
11.2.7.5. Regional
Bifurcation
11.2.7.5.1. North
America
11.2.7.5.1.1. Market
Estimation, 2015 – 2019
11.2.7.5.1.2. Market
Forecast, 2020 – 2028
11.2.7.5.2. Europe
11.2.7.5.2.1. Market
Estimation, 2015 – 2019
11.2.7.5.2.2. Market
Forecast, 2020 – 2028
11.2.7.5.3. Asia
Pacific
11.2.7.5.3.1. Market
Estimation, 2015 – 2019
11.2.7.5.3.2. Market
Forecast, 2020 – 2028
11.2.7.5.4. Middle
East and Africa
11.2.7.5.4.1. Market
Estimation, 2015 – 2019
11.2.7.5.4.2. Market
Forecast, 2020 – 2028
11.2.7.5.5. Latin
America
11.2.7.5.5.1. Market
Estimation, 2015 – 2019
11.2.7.5.5.2. Market
Forecast, 2020 – 2028
11.2.8. Respiratory
Syndromes
11.2.8.1. Definition
11.2.8.2. Market
Estimation and Penetration, 2015 – 2019
11.2.8.3. Market
Forecast, 2020 – 2028
11.2.8.4. Compound
Annual Growth Rate (CAGR)
11.2.8.5. Regional
Bifurcation
11.2.8.5.1. North
America
11.2.8.5.1.1. Market
Estimation, 2015 – 2019
11.2.8.5.1.2. Market
Forecast, 2020 – 2028
11.2.8.5.2. Europe
11.2.8.5.2.1. Market
Estimation, 2015 – 2019
11.2.8.5.2.2. Market
Forecast, 2020 – 2028
11.2.8.5.3. Asia
Pacific
11.2.8.5.3.1. Market
Estimation, 2015 – 2019
11.2.8.5.3.2. Market
Forecast, 2020 – 2028
11.2.8.5.4. Middle
East and Africa
11.2.8.5.4.1. Market
Estimation, 2015 – 2019
11.2.8.5.4.2. Market
Forecast, 2020 – 2028
11.2.8.5.5. Latin
America
11.2.8.5.5.1. Market
Estimation, 2015 – 2019
11.2.8.5.5.2. Market
Forecast, 2020 – 2028
11.2.9. Cancer
11.2.9.1. Definition
11.2.9.2. Market
Estimation and Penetration, 2015 – 2019
11.2.9.3. Market
Forecast, 2020 – 2028
11.2.9.4. Compound
Annual Growth Rate (CAGR)
11.2.9.5. Regional
Bifurcation
11.2.9.5.1. North
America
11.2.9.5.1.1. Market
Estimation, 2015 – 2019
11.2.9.5.1.2. Market
Forecast, 2020 – 2028
11.2.9.5.2. Europe
11.2.9.5.2.1. Market
Estimation, 2015 – 2019
11.2.9.5.2.2. Market
Forecast, 2020 – 2028
11.2.9.5.3. Asia
Pacific
11.2.9.5.3.1. Market
Estimation, 2015 – 2019
11.2.9.5.3.2. Market
Forecast, 2020 – 2028
11.2.9.5.4. Middle
East and Africa
11.2.9.5.4.1. Market
Estimation, 2015 – 2019
11.2.9.5.4.2. Market
Forecast, 2020 – 2028
11.2.9.5.5. Latin
America
11.2.9.5.5.1. Market
Estimation, 2015 – 2019
11.2.9.5.5.2. Market
Forecast, 2020 – 2028
11.2.10. Others
11.2.10.1. Definition
11.2.10.2. Market
Estimation and Penetration, 2015 – 2019
11.2.10.3. Market
Forecast, 2020 – 2028
11.2.10.4. Compound
Annual Growth Rate (CAGR)
11.2.10.5. Regional
Bifurcation
11.2.10.5.1. North
America
11.2.10.5.1.1. Market
Estimation, 2015 – 2019
11.2.10.5.1.2. Market
Forecast, 2020 – 2028
11.2.10.5.2. Europe
11.2.10.5.2.1. Market
Estimation, 2015 – 2019
11.2.10.5.2.2. Market
Forecast, 2020 – 2028
11.2.10.5.3. Asia
Pacific
11.2.10.5.3.1. Market
Estimation, 2015 – 2019
11.2.10.5.3.2. Market
Forecast, 2020 – 2028
11.2.10.5.4. Middle
East and Africa
11.2.10.5.4.1. Market
Estimation, 2015 – 2019
11.2.10.5.4.2. Market
Forecast, 2020 – 2028
11.2.10.5.5. Latin
America
11.2.10.5.5.1. Market
Estimation, 2015 – 2019
11.2.10.5.5.2. Market
Forecast, 2020 – 2028
11.3. Key
Segment for Channeling Investments
11.3.1. By
Disease Indication
12. Global Plant-based Vaccines Market Analysis and Forecasts,
2020 – 2028
12.1. Overview
12.2. Global
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Mode of
Administration
12.2.1. Intramuscular
12.2.1.1. Definition
12.2.1.2. Market
Estimation and Penetration, 2015 – 2019
12.2.1.3. Market
Forecast, 2020 – 2028
12.2.1.4. Compound
Annual Growth Rate (CAGR)
12.2.1.5. Regional
Bifurcation
12.2.1.5.1. North
America
12.2.1.5.1.1. Market
Estimation, 2015 – 2019
12.2.1.5.1.2. Market
Forecast, 2020 – 2028
12.2.1.5.2. Europe
12.2.1.5.2.1. Market
Estimation, 2015 – 2019
12.2.1.5.2.2. Market
Forecast, 2020 – 2028
12.2.1.5.3. Asia
Pacific
12.2.1.5.3.1. Market
Estimation, 2015 – 2019
12.2.1.5.3.2. Market
Forecast, 2020 – 2028
12.2.1.5.4. Middle
East and Africa
12.2.1.5.4.1. Market
Estimation, 2015 – 2019
12.2.1.5.4.2. Market
Forecast, 2020 – 2028
12.2.1.5.5. Latin
America
12.2.1.5.5.1. Market
Estimation, 2015 – 2019
12.2.1.5.5.2. Market
Forecast, 2020 – 2028
12.2.2. Oral
Administration
12.2.2.1. Definition
12.2.2.2. Market
Estimation and Penetration, 2015 – 2019
12.2.2.3. Market
Forecast, 2020 – 2028
12.2.2.4. Compound
Annual Growth Rate (CAGR)
12.2.2.5. Regional
Bifurcation
12.2.2.5.1. North
America
12.2.2.5.1.1. Market
Estimation, 2015 – 2019
12.2.2.5.1.2. Market
Forecast, 2020 – 2028
12.2.2.5.2. Europe
12.2.2.5.2.1. Market
Estimation, 2015 – 2019
12.2.2.5.2.2. Market
Forecast, 2020 – 2028
12.2.2.5.3. Asia
Pacific
12.2.2.5.3.1. Market
Estimation, 2015 – 2019
12.2.2.5.3.2. Market
Forecast, 2020 – 2028
12.2.2.5.4. Middle
East and Africa
12.2.2.5.4.1. Market
Estimation, 2015 – 2019
12.2.2.5.4.2. Market
Forecast, 2020 – 2028
12.2.2.5.5. Latin
America
12.2.2.5.5.1. Market
Estimation, 2015 – 2019
12.2.2.5.5.2. Market
Forecast, 2020 – 2028
12.2.3. Others
12.2.3.1. Definition
12.2.3.2. Market
Estimation and Penetration, 2015 – 2019
12.2.3.3. Market
Forecast, 2020 – 2028
12.2.3.4. Compound
Annual Growth Rate (CAGR)
12.2.3.5. Regional
Bifurcation
12.2.3.5.1. North
America
12.2.3.5.1.1. Market
Estimation, 2015 – 2019
12.2.3.5.1.2. Market
Forecast, 2020 – 2028
12.2.3.5.2. Europe
12.2.3.5.2.1. Market
Estimation, 2015 – 2019
12.2.3.5.2.2. Market
Forecast, 2020 – 2028
12.2.3.5.3. Asia
Pacific
12.2.3.5.3.1. Market
Estimation, 2015 – 2019
12.2.3.5.3.2. Market
Forecast, 2020 – 2028
12.2.3.5.4. Middle
East and Africa
12.2.3.5.4.1. Market
Estimation, 2015 – 2019
12.2.3.5.4.2. Market
Forecast, 2020 – 2028
12.2.3.5.5. Latin
America
12.2.3.5.5.1. Market
Estimation, 2015 – 2019
12.2.3.5.5.2. Market
Forecast, 2020 – 2028
12.3. Key
Segment for Channeling Investments
12.3.1. By Mode
of Administration
13. Global Plant-based Vaccines Market Analysis and Forecasts,
2020 – 2028
13.1. Overview
13.2. Global
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By End Users
13.2.1. Hospitals
13.2.1.1. Definition
13.2.1.2. Market
Estimation and Penetration, 2015 – 2019
13.2.1.3. Market
Forecast, 2020 – 2028
13.2.1.4. Compound
Annual Growth Rate (CAGR)
13.2.1.5. Regional
Bifurcation
13.2.1.5.1. North
America
13.2.1.5.1.1. Market
Estimation, 2015 – 2019
13.2.1.5.1.2. Market
Forecast, 2020 – 2028
13.2.1.5.2. Europe
13.2.1.5.2.1. Market
Estimation, 2015 – 2019
13.2.1.5.2.2. Market
Forecast, 2020 – 2028
13.2.1.5.3. Asia
Pacific
13.2.1.5.3.1. Market
Estimation, 2015 – 2019
13.2.1.5.3.2. Market
Forecast, 2020 – 2028
13.2.1.5.4. Middle
East and Africa
13.2.1.5.4.1. Market
Estimation, 2015 – 2019
13.2.1.5.4.2. Market
Forecast, 2020 – 2028
13.2.1.5.5. Latin
America
13.2.1.5.5.1. Market
Estimation, 2015 – 2019
13.2.1.5.5.2. Market
Forecast, 2020 – 2028
13.2.2. Clinics
13.2.2.1. Definition
13.2.2.2. Market
Estimation and Penetration, 2015 – 2019
13.2.2.3. Market
Forecast, 2020 – 2028
13.2.2.4. Compound
Annual Growth Rate (CAGR)
13.2.2.5. Regional
Bifurcation
13.2.2.5.1. North
America
13.2.2.5.1.1. Market
Estimation, 2015 – 2019
13.2.2.5.1.2. Market
Forecast, 2020 – 2028
13.2.2.5.2. Europe
13.2.2.5.2.1. Market
Estimation, 2015 – 2019
13.2.2.5.2.2. Market
Forecast, 2020 – 2028
13.2.2.5.3. Asia
Pacific
13.2.2.5.3.1. Market
Estimation, 2015 – 2019
13.2.2.5.3.2. Market
Forecast, 2020 – 2028
13.2.2.5.4. Middle
East and Africa
13.2.2.5.4.1. Market
Estimation, 2015 – 2019
13.2.2.5.4.2. Market
Forecast, 2020 – 2028
13.2.2.5.5. Latin
America
13.2.2.5.5.1. Market
Estimation, 2015 – 2019
13.2.2.5.5.2. Market
Forecast, 2020 – 2028
13.2.3. Primary
Care Centers
13.2.3.1. Definition
13.2.3.2. Market
Estimation and Penetration, 2015 – 2019
13.2.3.3. Market
Forecast, 2020 – 2028
13.2.3.4. Compound
Annual Growth Rate (CAGR)
13.2.3.5. Regional
Bifurcation
13.2.3.5.1. North
America
13.2.3.5.1.1. Market
Estimation, 2015 – 2019
13.2.3.5.1.2. Market
Forecast, 2020 – 2028
13.2.3.5.2. Europe
13.2.3.5.2.1. Market
Estimation, 2015 – 2019
13.2.3.5.2.2. Market
Forecast, 2020 – 2028
13.2.3.5.3. Asia
Pacific
13.2.3.5.3.1. Market
Estimation, 2015 – 2019
13.2.3.5.3.2. Market
Forecast, 2020 – 2028
13.2.3.5.4. Middle
East and Africa
13.2.3.5.4.1. Market
Estimation, 2015 – 2019
13.2.3.5.4.2. Market
Forecast, 2020 – 2028
13.2.3.5.5. Latin
America
13.2.3.5.5.1. Market
Estimation, 2015 – 2019
13.2.3.5.5.2. Market
Forecast, 2020 – 2028
13.2.4. Others
13.2.4.1. Definition
13.2.4.2. Market
Estimation and Penetration, 2015 – 2019
13.2.4.3. Market
Forecast, 2020 – 2028
13.2.4.4. Compound
Annual Growth Rate (CAGR)
13.2.4.5. Regional
Bifurcation
13.2.4.5.1. North
America
13.2.4.5.1.1. Market
Estimation, 2015 – 2019
13.2.4.5.1.2. Market
Forecast, 2020 – 2028
13.2.4.5.2. Europe
13.2.4.5.2.1. Market
Estimation, 2015 – 2019
13.2.4.5.2.2. Market
Forecast, 2020 – 2028
13.2.4.5.3. Asia
Pacific
13.2.4.5.3.1. Market
Estimation, 2015 – 2019
13.2.4.5.3.2. Market
Forecast, 2020 – 2028
13.2.4.5.4. Middle
East and Africa
13.2.4.5.4.1. Market
Estimation, 2015 – 2019
13.2.4.5.4.2. Market
Forecast, 2020 – 2028
13.2.4.5.5. Latin
America
13.2.4.5.5.1. Market
Estimation, 2015 – 2019
13.2.4.5.5.2. Market
Forecast, 2020 – 2028
13.3. Key
Segment for Channeling Investments
13.3.1. By End
Users
14. North America Plant-based Vaccines Market Analysis and
Forecasts, 2020 - 2028
14.1. Overview
14.1.1. North
America Plant-based Vaccines Market Revenue (US$ Mn)
14.2. North
America Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Clinical
Trial
14.2.1. Phase I
14.2.2. Phase
II
14.2.3. Others
14.3. North
America Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Type
14.3.1. Bacterial/
Agrobacterial vaccines
14.3.2. Transgenic
14.3.3. Viral
Vaccines
14.3.4. Fungal
Vaccines
14.3.5. Recombinant
subunit vaccines
14.3.6. Parasitic
Vaccines
14.3.7. Others
14.4. North
America Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Source
14.4.1. Tobacco,
potato
14.4.2. Maize
14.4.3. Nicotiana
benthamiana
14.4.4. Carrot
cells, tobacco cells
14.4.5. Strawberry
14.4.6. Rice
14.4.7. Lettuce
14.4.8. Spinach
14.4.9. Others
14.5. North
America Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Disease Indication
14.5.1. Enterotoxigenic
E. coli
14.5.2. Ebola
virus
14.5.2.1. SUDV
14.5.2.2. ZEBOV
14.5.2.3. Côte
d’Ivoire ebolavirus
14.5.2.4. Bundibugyo
ebolavirus
14.5.3. Norovirus
14.5.4. Hepatitis
B virus
14.5.5. Rabies
14.5.6. Influenza
14.5.6.1. H1N1
14.5.6.2. H5N1
14.5.6.3. H7N9
14.5.6.4. Others
14.5.7. Cholera
14.5.8. Respiratory
Syndromes
14.5.9. Cancer
14.5.10. Others
14.6. North
America Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Mode of
Administration
14.6.1. Intramuscular
14.6.2. Oral
Administration
14.6.3. Others
14.7. North
America Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By End
Users
14.7.1. Hospitals
14.7.2. Clinics
14.7.3. Primary
Care Centers
14.7.4. Others
14.8. North
America Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Country
14.8.1. U.S
14.8.1.1. U.S
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Clinical Trial
14.8.1.1.1. Phase
I
14.8.1.1.2. Phase
II
14.8.1.1.3. Others
14.8.1.2. U.S
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Type
14.8.1.2.1. Bacterial/
Agrobacterial vaccines
14.8.1.2.2. Transgenic
14.8.1.2.3. Viral
Vaccines
14.8.1.2.4. Fungal
Vaccines
14.8.1.2.5. Recombinant
subunit vaccines
14.8.1.2.6. Parasitic
Vaccines
14.8.1.2.7. Others
14.8.1.3. U.S
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Source
14.8.1.3.1. Tobacco,
potato
14.8.1.3.2. Maize
14.8.1.3.3. Nicotiana
benthamiana
14.8.1.3.4. Carrot
cells, tobacco cells
14.8.1.3.5. Strawberry
14.8.1.3.6. Rice
14.8.1.3.7. Lettuce
14.8.1.3.8. Spinach
14.8.1.3.9. Others
14.8.1.4. U.S
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
14.8.1.4.1. Enterotoxigenic
E. coli
14.8.1.4.2. Ebola
virus
14.8.1.4.2.1. SUDV
14.8.1.4.2.2. ZEBOV
14.8.1.4.2.3. Côte
d’Ivoire ebolavirus
14.8.1.4.2.4. Bundibugyo
ebolavirus
14.8.1.4.3. Norovirus
14.8.1.4.4. Hepatitis
B virus
14.8.1.4.5. Rabies
14.8.1.4.6. Influenza
14.8.1.4.6.1. H1N1
14.8.1.4.6.2. H5N1
14.8.1.4.6.3. H7N9
14.8.1.4.6.4. Others
14.8.1.4.7. Cholera
14.8.1.4.8. Respiratory
Syndromes
14.8.1.4.9. Cancer
14.8.1.4.10. Others
14.8.1.5. U.S
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Mode of
Administration
14.8.1.5.1. Intramuscular
14.8.1.5.2. Oral
Administration
14.8.1.5.3. Others
14.8.1.6. U.S
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By End Users
14.8.1.6.1. Hospitals
14.8.1.6.2. Clinics
14.8.1.6.3. Primary
Care Centers
14.8.1.6.4. Others
14.8.2. Canada
14.8.2.1. Canada
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Clinical Trial
14.8.2.1.1. Phase
I
14.8.2.1.2. Phase
II
14.8.2.1.3. Others
14.8.2.2. Canada
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Type
14.8.2.2.1. Bacterial/
Agrobacterial vaccines
14.8.2.2.2. Transgenic
14.8.2.2.3. Viral
Vaccines
14.8.2.2.4. Fungal
Vaccines
14.8.2.2.5. Recombinant
subunit vaccines
14.8.2.2.6. Parasitic
Vaccines
14.8.2.2.7. Others
14.8.2.3. Canada
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Source
14.8.2.3.1. Tobacco,
potato
14.8.2.3.2. Maize
14.8.2.3.3. Nicotiana
benthamiana
14.8.2.3.4. Carrot
cells, tobacco cells
14.8.2.3.5. Strawberry
14.8.2.3.6. Rice
14.8.2.3.7. Lettuce
14.8.2.3.8. Spinach
14.8.2.3.9. Others
14.8.2.4. Canada
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
14.8.2.4.1. Enterotoxigenic
E. coli
14.8.2.4.2. Ebola
virus
14.8.2.4.2.1. SUDV
14.8.2.4.2.2. ZEBOV
14.8.2.4.2.3. Côte
d’Ivoire ebolavirus
14.8.2.4.2.4. Bundibugyo
ebolavirus
14.8.2.4.3. Norovirus
14.8.2.4.4. Hepatitis
B virus
14.8.2.4.5. Rabies
14.8.2.4.6. Influenza
14.8.2.4.6.1. H1N1
14.8.2.4.6.2. H5N1
14.8.2.4.6.3. H7N9
14.8.2.4.6.4. Others
14.8.2.4.7. Cholera
14.8.2.4.8. Respiratory
Syndromes
14.8.2.4.9. Cancer
14.8.2.4.10. Others
14.8.2.5. Canada
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Mode of
Administration
14.8.2.5.1. Intramuscular
14.8.2.5.2. Oral
Administration
14.8.2.5.3. Others
14.8.2.6. Canada
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By End Users
14.8.2.6.1. Hospitals
14.8.2.6.2. Clinics
14.8.2.6.3. Primary
Care Centers
14.8.2.6.4. Others
14.8.3. Mexico
14.8.3.1. Mexico
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Clinical Trial
14.8.3.1.1. Phase
I
14.8.3.1.2. Phase
II
14.8.3.1.3. Others
14.8.3.2. Mexico
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Type
14.8.3.2.1. Bacterial/
Agrobacterial vaccines
14.8.3.2.2. Transgenic
14.8.3.2.3. Viral
Vaccines
14.8.3.2.4. Fungal
Vaccines
14.8.3.2.5. Recombinant
subunit vaccines
14.8.3.2.6. Parasitic
Vaccines
14.8.3.2.7. Others
14.8.3.3. Mexico
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Source
14.8.3.3.1. Tobacco,
potato
14.8.3.3.2. Maize
14.8.3.3.3. Nicotiana
benthamiana
14.8.3.3.4. Carrot
cells, tobacco cells
14.8.3.3.5. Strawberry
14.8.3.3.6. Rice
14.8.3.3.7. Lettuce
14.8.3.3.8. Spinach
14.8.3.3.9. Others
14.8.3.4. Mexico
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
14.8.3.4.1. Enterotoxigenic
E. coli
14.8.3.4.2. Ebola
virus
14.8.3.4.2.1. SUDV
14.8.3.4.2.2. ZEBOV
14.8.3.4.2.3. Côte
d’Ivoire ebolavirus
14.8.3.4.2.4. Bundibugyo
ebolavirus
14.8.3.4.3. Norovirus
14.8.3.4.4. Hepatitis
B virus
14.8.3.4.5. Rabies
14.8.3.4.6. Influenza
14.8.3.4.6.1. H1N1
14.8.3.4.6.2. H5N1
14.8.3.4.6.3. H7N9
14.8.3.4.6.4. Others
14.8.3.4.7. Cholera
14.8.3.4.8. Respiratory
Syndromes
14.8.3.4.9. Cancer
14.8.3.4.10. Others
14.8.3.5. Mexico
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Mode of
Administration
14.8.3.5.1. Intramuscular
14.8.3.5.2. Oral
Administration
14.8.3.5.3. Others
14.8.3.6. Mexico
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By End Users
14.8.3.6.1. Hospitals
14.8.3.6.2. Clinics
14.8.3.6.3. Primary
Care Centers
14.8.3.6.4. Others
14.8.4. Rest of
North America
14.8.4.1. Rest
of North America Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By
Clinical Trial
14.8.4.1.1. Phase
I
14.8.4.1.2. Phase
II
14.8.4.1.3. Others
14.8.4.2. Rest
of North America Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By
Type
14.8.4.2.1. Bacterial/
Agrobacterial vaccines
14.8.4.2.2. Transgenic
14.8.4.2.3. Viral
Vaccines
14.8.4.2.4. Fungal
Vaccines
14.8.4.2.5. Recombinant
subunit vaccines
14.8.4.2.6. Parasitic
Vaccines
14.8.4.2.7. Others
14.8.4.3. Rest
of North America Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By
Source
14.8.4.3.1. Tobacco,
potato
14.8.4.3.2. Maize
14.8.4.3.3. Nicotiana
benthamiana
14.8.4.3.4. Carrot
cells, tobacco cells
14.8.4.3.5. Strawberry
14.8.4.3.6. Rice
14.8.4.3.7. Lettuce
14.8.4.3.8. Spinach
14.8.4.3.9. Others
14.8.4.4. Rest
of North America Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By
Disease Indication
14.8.4.4.1. Enterotoxigenic
E. coli
14.8.4.4.2. Ebola
virus
14.8.4.4.2.1. SUDV
14.8.4.4.2.2. ZEBOV
14.8.4.4.2.3. Côte
d’Ivoire ebolavirus
14.8.4.4.2.4. Bundibugyo
ebolavirus
14.8.4.4.3. Norovirus
14.8.4.4.4. Hepatitis
B virus
14.8.4.4.5. Rabies
14.8.4.4.6. Influenza
14.8.4.4.6.1. H1N1
14.8.4.4.6.2. H5N1
14.8.4.4.6.3. H7N9
14.8.4.4.6.4. Others
14.8.4.4.7. Cholera
14.8.4.4.8. Respiratory
Syndromes
14.8.4.4.9. Cancer
14.8.4.4.10. Others
14.8.4.5. Rest
of North America Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By
Mode of Administration
14.8.4.5.1. Intramuscular
14.8.4.5.2. Oral
Administration
14.8.4.5.3. Others
14.8.4.6. Rest
of North America Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By
End Users
14.8.4.6.1. Hospitals
14.8.4.6.2. Clinics
14.8.4.6.3. Primary
Care Centers
14.8.4.6.4. Others
14.9. Key
Segment for Channeling Investments
14.9.1. By
Country
14.9.2. By
Clinical Trial
14.9.3. By Type
14.9.4. By
Source
14.9.5. By
Disease Indication
14.9.6. By Mode
of Administration
14.9.7. By End
Users
15. Europe Plant-based Vaccines Market Analysis and Forecasts,
2020 - 2028
15.1. Overview
15.1.1. Europe
Plant-based Vaccines Market Revenue (US$ Mn)
15.2. Europe
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Clinical Trial
15.2.1. Phase I
15.2.2. Phase
II
15.2.3. Others
15.3. Europe
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Type
15.3.1. Bacterial/
Agrobacterial vaccines
15.3.2. Transgenic
15.3.3. Viral
Vaccines
15.3.4. Fungal
Vaccines
15.3.5. Recombinant
subunit vaccines
15.3.6. Parasitic
Vaccines
15.3.7. Others
15.4. Europe
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Source
15.4.1. Tobacco,
potato
15.4.2. Maize
15.4.3. Nicotiana
benthamiana
15.4.4. Carrot
cells, tobacco cells
15.4.5. Strawberry
15.4.6. Rice
15.4.7. Lettuce
15.4.8. Spinach
15.4.9. Others
15.5. Europe
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
15.5.1. Enterotoxigenic
E. coli
15.5.2. Ebola
virus
15.5.2.1. SUDV
15.5.2.2. ZEBOV
15.5.2.3. Côte
d’Ivoire ebolavirus
15.5.2.4. Bundibugyo
ebolavirus
15.5.3. Norovirus
15.5.4. Hepatitis
B virus
15.5.5. Rabies
15.5.6. Influenza
15.5.6.1. H1N1
15.5.6.2. H5N1
15.5.6.3. H7N9
15.5.6.4. Others
15.5.7. Cholera
15.5.8. Respiratory
Syndromes
15.5.9. Cancer
15.5.10. Others
15.6. Europe
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Mode of
Administration
15.6.1. Intramuscular
15.6.2. Oral Administration
15.6.3. Others
15.7. Europe
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By End Users
15.7.1. Hospitals
15.7.2. Clinics
15.7.3. Primary
Care Centers
15.7.4. Others
15.8. Europe
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Country
15.8.1. France
15.8.1.1. France
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Clinical Trial
15.8.1.1.1. Phase
I
15.8.1.1.2. Phase
II
15.8.1.1.3. Others
15.8.1.2. France
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Type
15.8.1.2.1. Bacterial/
Agrobacterial vaccines
15.8.1.2.2. Transgenic
15.8.1.2.3. Viral
Vaccines
15.8.1.2.4. Fungal
Vaccines
15.8.1.2.5. Recombinant
subunit vaccines
15.8.1.2.6. Parasitic
Vaccines
15.8.1.2.7. Others
15.8.1.3. France
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Source
15.8.1.3.1. Tobacco,
potato
15.8.1.3.2. Maize
15.8.1.3.3. Nicotiana
benthamiana
15.8.1.3.4. Carrot
cells, tobacco cells
15.8.1.3.5. Strawberry
15.8.1.3.6. Rice
15.8.1.3.7. Lettuce
15.8.1.3.8. Spinach
15.8.1.3.9. Others
15.8.1.4. France
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
15.8.1.4.1. Enterotoxigenic
E. coli
15.8.1.4.2. Ebola
virus
15.8.1.4.2.1. SUDV
15.8.1.4.2.2. ZEBOV
15.8.1.4.2.3. Côte
d’Ivoire ebolavirus
15.8.1.4.2.4. Bundibugyo
ebolavirus
15.8.1.4.3. Norovirus
15.8.1.4.4. Hepatitis
B virus
15.8.1.4.5. Rabies
15.8.1.4.6. Influenza
15.8.1.4.6.1. H1N1
15.8.1.4.6.2. H5N1
15.8.1.4.6.3. H7N9
15.8.1.4.6.4. Others
15.8.1.4.7. Cholera
15.8.1.4.8. Respiratory
Syndromes
15.8.1.4.9. Cancer
15.8.1.4.10. Others
15.8.1.5. France
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Mode of
Administration
15.8.1.5.1. Intramuscular
15.8.1.5.2. Oral
Administration
15.8.1.5.3. Others
15.8.1.6. France
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By End Users
15.8.1.6.1. Hospitals
15.8.1.6.2. Clinics
15.8.1.6.3. Primary
Care Centers
15.8.1.6.4. Others
15.8.2. The UK
15.8.2.1. The
UK Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Clinical
Trial
15.8.2.1.1. Phase
I
15.8.2.1.2. Phase
II
15.8.2.1.3. Others
15.8.2.2. The
UK Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Type
15.8.2.2.1. Bacterial/
Agrobacterial vaccines
15.8.2.2.2. Transgenic
15.8.2.2.3. Viral
Vaccines
15.8.2.2.4. Fungal
Vaccines
15.8.2.2.5. Recombinant
subunit vaccines
15.8.2.2.6. Parasitic
Vaccines
15.8.2.2.7. Others
15.8.2.3. The
UK Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Source
15.8.2.3.1. Tobacco,
potato
15.8.2.3.2. Maize
15.8.2.3.3. Nicotiana
benthamiana
15.8.2.3.4. Carrot
cells, tobacco cells
15.8.2.3.5. Strawberry
15.8.2.3.6. Rice
15.8.2.3.7. Lettuce
15.8.2.3.8. Spinach
15.8.2.3.9. Others
15.8.2.4. The
UK Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
15.8.2.4.1. Enterotoxigenic
E. coli
15.8.2.4.2. Ebola
virus
15.8.2.4.2.1. SUDV
15.8.2.4.2.2. ZEBOV
15.8.2.4.2.3. Côte
d’Ivoire ebolavirus
15.8.2.4.2.4. Bundibugyo
ebolavirus
15.8.2.4.3. Norovirus
15.8.2.4.4. Hepatitis
B virus
15.8.2.4.5. Rabies
15.8.2.4.6. Influenza
15.8.2.4.6.1. H1N1
15.8.2.4.6.2. H5N1
15.8.2.4.6.3. H7N9
15.8.2.4.6.4. Others
15.8.2.4.7. Cholera
15.8.2.4.8. Respiratory
Syndromes
15.8.2.4.9. Cancer
15.8.2.4.10. Others
15.8.2.5. The
UK Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Mode of
Administration
15.8.2.5.1. Intramuscular
15.8.2.5.2. Oral
Administration
15.8.2.5.3. Others
15.8.2.6. The
UK Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By End Users
15.8.2.6.1. Hospitals
15.8.2.6.2. Clinics
15.8.2.6.3. Primary
Care Centers
15.8.2.6.4. Others
15.8.3. Spain
15.8.3.1. Spain
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Clinical Trial
15.8.3.1.1. Phase
I
15.8.3.1.2. Phase
II
15.8.3.1.3. Others
15.8.3.2. Spain
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Type
15.8.3.2.1. Bacterial/
Agrobacterial vaccines
15.8.3.2.2. Transgenic
15.8.3.2.3. Viral
Vaccines
15.8.3.2.4. Fungal
Vaccines
15.8.3.2.5. Recombinant
subunit vaccines
15.8.3.2.6. Parasitic
Vaccines
15.8.3.2.7. Others
15.8.3.3. Spain
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Source
15.8.3.3.1. Tobacco,
potato
15.8.3.3.2. Maize
15.8.3.3.3. Nicotiana
benthamiana
15.8.3.3.4. Carrot
cells, tobacco cells
15.8.3.3.5. Strawberry
15.8.3.3.6. Rice
15.8.3.3.7. Lettuce
15.8.3.3.8. Spinach
15.8.3.3.9. Others
15.8.3.4. Spain
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
15.8.3.4.1. Enterotoxigenic
E. coli
15.8.3.4.2. Ebola
virus
15.8.3.4.2.1. SUDV
15.8.3.4.2.2. ZEBOV
15.8.3.4.2.3. Côte
d’Ivoire ebolavirus
15.8.3.4.2.4. Bundibugyo
ebolavirus
15.8.3.4.3. Norovirus
15.8.3.4.4. Hepatitis
B virus
15.8.3.4.5. Rabies
15.8.3.4.6. Influenza
15.8.3.4.6.1. H1N1
15.8.3.4.6.2. H5N1
15.8.3.4.6.3. H7N9
15.8.3.4.6.4. Others
15.8.3.4.7. Cholera
15.8.3.4.8. Respiratory
Syndromes
15.8.3.4.9. Cancer
15.8.3.4.10. Others
15.8.3.5. Spain
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Mode of
Administration
15.8.3.5.1. Intramuscular
15.8.3.5.2. Oral
Administration
15.8.3.5.3. Others
15.8.3.6. Spain
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By End Users
15.8.3.6.1. Hospitals
15.8.3.6.2. Clinics
15.8.3.6.3. Primary
Care Centers
15.8.3.6.4. Others
15.8.4. Germany
15.8.4.1. Germany
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Clinical Trial
15.8.4.1.1. Phase
I
15.8.4.1.2. Phase
II
15.8.4.1.3. Others
15.8.4.2. Germany
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Type
15.8.4.2.1. Bacterial/
Agrobacterial vaccines
15.8.4.2.2. Transgenic
15.8.4.2.3. Viral
Vaccines
15.8.4.2.4. Fungal
Vaccines
15.8.4.2.5. Recombinant
subunit vaccines
15.8.4.2.6. Parasitic
Vaccines
15.8.4.2.7. Others
15.8.4.3. Germany
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Source
15.8.4.3.1. Tobacco,
potato
15.8.4.3.2. Maize
15.8.4.3.3. Nicotiana
benthamiana
15.8.4.3.4. Carrot
cells, tobacco cells
15.8.4.3.5. Strawberry
15.8.4.3.6. Rice
15.8.4.3.7. Lettuce
15.8.4.3.8. Spinach
15.8.4.3.9. Others
15.8.4.4. Germany
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
15.8.4.4.1. Enterotoxigenic
E. coli
15.8.4.4.2. Ebola
virus
15.8.4.4.2.1. SUDV
15.8.4.4.2.2. ZEBOV
15.8.4.4.2.3. Côte
d’Ivoire ebolavirus
15.8.4.4.2.4. Bundibugyo
ebolavirus
15.8.4.4.3. Norovirus
15.8.4.4.4. Hepatitis
B virus
15.8.4.4.5. Rabies
15.8.4.4.6. Influenza
15.8.4.4.6.1. H1N1
15.8.4.4.6.2. H5N1
15.8.4.4.6.3. H7N9
15.8.4.4.6.4. Others
15.8.4.4.7. Cholera
15.8.4.4.8. Respiratory
Syndromes
15.8.4.4.9. Cancer
15.8.4.4.10. Others
15.8.4.5. Germany
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Mode of
Administration
15.8.4.5.1. Intramuscular
15.8.4.5.2. Oral
Administration
15.8.4.5.3. Others
15.8.4.6. Germany
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By End Users
15.8.4.6.1. Hospitals
15.8.4.6.2. Clinics
15.8.4.6.3. Primary
Care Centers
15.8.4.6.4. Others
15.8.5. Italy
15.8.5.1. Italy
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Clinical Trial
15.8.5.1.1. Phase
I
15.8.5.1.2. Phase
II
15.8.5.1.3. Others
15.8.5.2. Italy
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Type
15.8.5.2.1. Bacterial/
Agrobacterial vaccines
15.8.5.2.2. Transgenic
15.8.5.2.3. Viral
Vaccines
15.8.5.2.4. Fungal
Vaccines
15.8.5.2.5. Recombinant
subunit vaccines
15.8.5.2.6. Parasitic
Vaccines
15.8.5.2.7. Others
15.8.5.3. Italy
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Source
15.8.5.3.1. Tobacco,
potato
15.8.5.3.2. Maize
15.8.5.3.3. Nicotiana
benthamiana
15.8.5.3.4. Carrot
cells, tobacco cells
15.8.5.3.5. Strawberry
15.8.5.3.6. Rice
15.8.5.3.7. Lettuce
15.8.5.3.8. Spinach
15.8.5.3.9. Others
15.8.5.4. Italy
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
15.8.5.4.1. Enterotoxigenic
E. coli
15.8.5.4.2. Ebola
virus
15.8.5.4.2.1. SUDV
15.8.5.4.2.2. ZEBOV
15.8.5.4.2.3. Côte
d’Ivoire ebolavirus
15.8.5.4.2.4. Bundibugyo
ebolavirus
15.8.5.4.3. Norovirus
15.8.5.4.4. Hepatitis
B virus
15.8.5.4.5. Rabies
15.8.5.4.6. Influenza
15.8.5.4.6.1. H1N1
15.8.5.4.6.2. H5N1
15.8.5.4.6.3. H7N9
15.8.5.4.6.4. Others
15.8.5.4.7. Cholera
15.8.5.4.8. Respiratory
Syndromes
15.8.5.4.9. Cancer
15.8.5.4.10. Others
15.8.5.5. Italy
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Mode of
Administration
15.8.5.5.1. Intramuscular
15.8.5.5.2. Oral
Administration
15.8.5.5.3. Others
15.8.5.6. Italy
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By End Users
15.8.5.6.1. Hospitals
15.8.5.6.2. Clinics
15.8.5.6.3. Primary
Care Centers
15.8.5.6.4. Others
15.8.6. Nordic
Countries
15.8.6.1. Nordic
Countries Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By
Clinical Trial
15.8.6.1.1. Phase
I
15.8.6.1.2. Phase
II
15.8.6.1.3. Others
15.8.6.2. Nordic
Countries Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Type
15.8.6.2.1. Bacterial/
Agrobacterial vaccines
15.8.6.2.2. Transgenic
15.8.6.2.3. Viral
Vaccines
15.8.6.2.4. Fungal
Vaccines
15.8.6.2.5. Recombinant
subunit vaccines
15.8.6.2.6. Parasitic
Vaccines
15.8.6.2.7. Others
15.8.6.3. Nordic
Countries Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Source
15.8.6.3.1. Tobacco,
potato
15.8.6.3.2. Maize
15.8.6.3.3. Nicotiana
benthamiana
15.8.6.3.4. Carrot
cells, tobacco cells
15.8.6.3.5. Strawberry
15.8.6.3.6. Rice
15.8.6.3.7. Lettuce
15.8.6.3.8. Spinach
15.8.6.3.9. Others
15.8.6.4. Nordic
Countries Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By
Disease Indication
15.8.6.4.1. Enterotoxigenic
E. coli
15.8.6.4.2. Ebola
virus
15.8.6.4.2.1. SUDV
15.8.6.4.2.2. ZEBOV
15.8.6.4.2.3. Côte
d’Ivoire ebolavirus
15.8.6.4.2.4. Bundibugyo
ebolavirus
15.8.6.4.3. Norovirus
15.8.6.4.4. Hepatitis
B virus
15.8.6.4.5. Rabies
15.8.6.4.6. Influenza
15.8.6.4.6.1. H1N1
15.8.6.4.6.2. H5N1
15.8.6.4.6.3. H7N9
15.8.6.4.6.4. Others
15.8.6.4.7. Cholera
15.8.6.4.8. Respiratory
Syndromes
15.8.6.4.9. Cancer
15.8.6.4.10. Others
15.8.6.5. Nordic
Countries Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Mode
of Administration
15.8.6.5.1. Intramuscular
15.8.6.5.2. Oral
Administration
15.8.6.5.3. Others
15.8.6.6. Nordic
Countries Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By End
Users
15.8.6.6.1. Hospitals
15.8.6.6.2. Clinics
15.8.6.6.3. Primary
Care Centers
15.8.6.6.4. Others
15.8.6.7. Nordic
Countries Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By
Country
15.8.6.7.1. Denmark
15.8.6.7.2. Finland
15.8.6.7.3. Iceland
15.8.6.7.4. Sweden
15.8.6.7.5. Norway
15.8.7. Benelux
Union
15.8.7.1. Benelux
Union Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Clinical
Trial
15.8.7.1.1. Phase
I
15.8.7.1.2. Phase
II
15.8.7.1.3. Others
15.8.7.2. Benelux
Union Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Type
15.8.7.2.1. Bacterial/
Agrobacterial vaccines
15.8.7.2.2. Transgenic
15.8.7.2.3. Viral
Vaccines
15.8.7.2.4. Fungal
Vaccines
15.8.7.2.5. Recombinant
subunit vaccines
15.8.7.2.6. Parasitic
Vaccines
15.8.7.2.7. Others
15.8.7.3. Benelux
Union Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Source
15.8.7.3.1. Tobacco,
potato
15.8.7.3.2. Maize
15.8.7.3.3. Nicotiana
benthamiana
15.8.7.3.4. Carrot
cells, tobacco cells
15.8.7.3.5. Strawberry
15.8.7.3.6. Rice
15.8.7.3.7. Lettuce
15.8.7.3.8. Spinach
15.8.7.3.9. Others
15.8.7.4. Benelux
Union Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
15.8.7.4.1. Enterotoxigenic
E. coli
15.8.7.4.2. Ebola
virus
15.8.7.4.2.1. SUDV
15.8.7.4.2.2. ZEBOV
15.8.7.4.2.3. Côte
d’Ivoire ebolavirus
15.8.7.4.2.4. Bundibugyo
ebolavirus
15.8.7.4.3. Norovirus
15.8.7.4.4. Hepatitis
B virus
15.8.7.4.5. Rabies
15.8.7.4.6. Influenza
15.8.7.4.6.1. H1N1
15.8.7.4.6.2. H5N1
15.8.7.4.6.3. H7N9
15.8.7.4.6.4. Others
15.8.7.4.7. Cholera
15.8.7.4.8. Respiratory
Syndromes
15.8.7.4.9. Cancer
15.8.7.4.10. Others
15.8.7.5. Benelux
Union Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Mode of
Administration
15.8.7.5.1. Intramuscular
15.8.7.5.2. Oral
Administration
15.8.7.5.3. Others
15.8.7.6. Benelux
Union Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By End Users
15.8.7.6.1. Hospitals
15.8.7.6.2. Clinics
15.8.7.6.3. Primary
Care Centers
15.8.7.6.4. Others
15.8.7.7. Benelux
Union Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Country
15.8.7.7.1. Belgium
15.8.7.7.2. The
Netherlands
15.8.7.7.3. Luxembourg
15.8.8. Rest of
Europe
15.8.8.1. Rest
of Europe Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Clinical
Trial
15.8.8.1.1. Phase
I
15.8.8.1.2. Phase
II
15.8.8.1.3. Others
15.8.8.2. Rest
of Europe Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Type
15.8.8.2.1. Bacterial/
Agrobacterial vaccines
15.8.8.2.2. Transgenic
15.8.8.2.3. Viral
Vaccines
15.8.8.2.4. Fungal
Vaccines
15.8.8.2.5. Recombinant
subunit vaccines
15.8.8.2.6. Parasitic
Vaccines
15.8.8.2.7. Others
15.8.8.3. Rest
of Europe Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Source
15.8.8.3.1. Tobacco,
potato
15.8.8.3.2. Maize
15.8.8.3.3. Nicotiana
benthamiana
15.8.8.3.4. Carrot
cells, tobacco cells
15.8.8.3.5. Strawberry
15.8.8.3.6. Rice
15.8.8.3.7. Lettuce
15.8.8.3.8. Spinach
15.8.8.3.9. Others
15.8.8.4. Rest
of Europe Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By
Disease Indication
15.8.8.4.1. Enterotoxigenic
E. coli
15.8.8.4.2. Ebola
virus
15.8.8.4.2.1. SUDV
15.8.8.4.2.2. ZEBOV
15.8.8.4.2.3. Côte
d’Ivoire ebolavirus
15.8.8.4.2.4. Bundibugyo
ebolavirus
15.8.8.4.3. Norovirus
15.8.8.4.4. Hepatitis
B virus
15.8.8.4.5. Rabies
15.8.8.4.6. Influenza
15.8.8.4.6.1. H1N1
15.8.8.4.6.2. H5N1
15.8.8.4.6.3. H7N9
15.8.8.4.6.4. Others
15.8.8.4.7. Cholera
15.8.8.4.8. Respiratory
Syndromes
15.8.8.4.9. Cancer
15.8.8.4.10. Others
15.8.8.5. Rest
of Europe Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Mode
of Administration
15.8.8.5.1. Intramuscular
15.8.8.5.2. Oral
Administration
15.8.8.5.3. Others
15.8.8.6. Rest
of Europe Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By End
Users
15.8.8.6.1. Hospitals
15.8.8.6.2. Clinics
15.8.8.6.3. Primary
Care Centers
15.8.8.6.4. Others
15.9. Key
Segment for Channeling Investments
15.9.1. By
Country
15.9.2. By
Clinical Trial
15.9.3. By Type
15.9.4. By
Source
15.9.5. By
Disease Indication
15.9.6. By Mode
of Administration
15.9.7. By End
Users
16. Asia Pacific Plant-based Vaccines Market Analysis and
Forecasts, 2020 - 2028
16.1. Overview
16.1.1. Asia
Pacific Plant-based Vaccines Market Revenue (US$ Mn)
16.2. Asia
Pacific Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Clinical
Trial
16.2.1. Phase I
16.2.2. Phase
II
16.2.3. Others
16.3. Asia
Pacific Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Type
16.3.1. Bacterial/
Agrobacterial vaccines
16.3.2. Transgenic
16.3.3. Viral
Vaccines
16.3.4. Fungal
Vaccines
16.3.5. Recombinant
subunit vaccines
16.3.6. Parasitic
Vaccines
16.3.7. Others
16.4. Asia
Pacific Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Source
16.4.1. Tobacco,
potato
16.4.2. Maize
16.4.3. Nicotiana
benthamiana
16.4.4. Carrot
cells, tobacco cells
16.4.5. Strawberry
16.4.6. Rice
16.4.7. Lettuce
16.4.8. Spinach
16.4.9. Others
16.5. Asia
Pacific Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
16.5.1. Enterotoxigenic
E. coli
16.5.2. Ebola
virus
16.5.2.1. SUDV
16.5.2.2. ZEBOV
16.5.2.3. Côte
d’Ivoire ebolavirus
16.5.2.4. Bundibugyo
ebolavirus
16.5.3. Norovirus
16.5.4. Hepatitis
B virus
16.5.5. Rabies
16.5.6. Influenza
16.5.6.1. H1N1
16.5.6.2. H5N1
16.5.6.3. H7N9
16.5.6.4. Others
16.5.7. Cholera
16.5.8. Respiratory
Syndromes
16.5.9. Cancer
16.5.10. Others
16.6. Asia
Pacific Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Mode of
Administration
16.6.1. Intramuscular
16.6.2. Oral
Administration
16.6.3. Others
16.7. Asia
Pacific Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By End
Users
16.7.1. Hospitals
16.7.2. Clinics
16.7.3. Primary
Care Centers
16.7.4. Others
16.8. Asia
Pacific Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Country
16.8.1. China
16.8.1.1. China
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Clinical Trial
16.8.1.1.1. Phase
I
16.8.1.1.2. Phase
II
16.8.1.1.3. Others
16.8.1.2. China
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Type
16.8.1.2.1. Bacterial/
Agrobacterial vaccines
16.8.1.2.2. Transgenic
16.8.1.2.3. Viral
Vaccines
16.8.1.2.4. Fungal
Vaccines
16.8.1.2.5. Recombinant
subunit vaccines
16.8.1.2.6. Parasitic
Vaccines
16.8.1.2.7. Others
16.8.1.3. China
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Source
16.8.1.3.1. Tobacco,
potato
16.8.1.3.2. Maize
16.8.1.3.3. Nicotiana
benthamiana
16.8.1.3.4. Carrot
cells, tobacco cells
16.8.1.3.5. Strawberry
16.8.1.3.6. Rice
16.8.1.3.7. Lettuce
16.8.1.3.8. Spinach
16.8.1.3.9. Others
16.8.1.4. China
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
16.8.1.4.1. Enterotoxigenic
E. coli
16.8.1.4.2. Ebola
virus
16.8.1.4.2.1. SUDV
16.8.1.4.2.2. ZEBOV
16.8.1.4.2.3. Côte
d’Ivoire ebolavirus
16.8.1.4.2.4. Bundibugyo
ebolavirus
16.8.1.4.3. Norovirus
16.8.1.4.4. Hepatitis
B virus
16.8.1.4.5. Rabies
16.8.1.4.6. Influenza
16.8.1.4.6.1. H1N1
16.8.1.4.6.2. H5N1
16.8.1.4.6.3. H7N9
16.8.1.4.6.4. Others
16.8.1.4.7. Cholera
16.8.1.4.8. Respiratory
Syndromes
16.8.1.4.9. Cancer
16.8.1.4.10. Others
16.8.1.5. China
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Mode of
Administration
16.8.1.5.1. Intramuscular
16.8.1.5.2. Oral
Administration
16.8.1.5.3. Others
16.8.1.6. China
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By End Users
16.8.1.6.1. Hospitals
16.8.1.6.2. Clinics
16.8.1.6.3. Primary
Care Centers
16.8.1.6.4. Others
16.8.2. Japan
16.8.2.1. Japan
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Clinical Trial
16.8.2.1.1. Phase
I
16.8.2.1.2. Phase
II
16.8.2.1.3. Others
16.8.2.2. Japan
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Type
16.8.2.2.1. Bacterial/
Agrobacterial vaccines
16.8.2.2.2. Transgenic
16.8.2.2.3. Viral
Vaccines
16.8.2.2.4. Fungal
Vaccines
16.8.2.2.5. Recombinant
subunit vaccines
16.8.2.2.6. Parasitic
Vaccines
16.8.2.2.7. Others
16.8.2.3. Japan
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Source
16.8.2.3.1. Tobacco,
potato
16.8.2.3.2. Maize
16.8.2.3.3. Nicotiana
benthamiana
16.8.2.3.4. Carrot
cells, tobacco cells
16.8.2.3.5. Strawberry
16.8.2.3.6. Rice
16.8.2.3.7. Lettuce
16.8.2.3.8. Spinach
16.8.2.3.9. Others
16.8.2.4. Japan
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
16.8.2.4.1. Enterotoxigenic
E. coli
16.8.2.4.2. Ebola
virus
16.8.2.4.2.1. SUDV
16.8.2.4.2.2. ZEBOV
16.8.2.4.2.3. Côte
d’Ivoire ebolavirus
16.8.2.4.2.4. Bundibugyo
ebolavirus
16.8.2.4.3. Norovirus
16.8.2.4.4. Hepatitis
B virus
16.8.2.4.5. Rabies
16.8.2.4.6. Influenza
16.8.2.4.6.1. H1N1
16.8.2.4.6.2. H5N1
16.8.2.4.6.3. H7N9
16.8.2.4.6.4. Others
16.8.2.4.7. Cholera
16.8.2.4.8. Respiratory
Syndromes
16.8.2.4.9. Cancer
16.8.2.4.10. Others
16.8.2.5. Japan
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Mode of
Administration
16.8.2.5.1. Intramuscular
16.8.2.5.2. Oral
Administration
16.8.2.5.3. Others
16.8.2.6. Japan
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By End Users
16.8.2.6.1. Hospitals
16.8.2.6.2. Clinics
16.8.2.6.3. Primary
Care Centers
16.8.2.6.4. Others
16.8.3. India
16.8.3.1. India
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Clinical Trial
16.8.3.1.1. Phase
I
16.8.3.1.2. Phase
II
16.8.3.1.3. Others
16.8.3.2. India
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Type
16.8.3.2.1. Bacterial/
Agrobacterial vaccines
16.8.3.2.2. Transgenic
16.8.3.2.3. Viral
Vaccines
16.8.3.2.4. Fungal
Vaccines
16.8.3.2.5. Recombinant
subunit vaccines
16.8.3.2.6. Parasitic
Vaccines
16.8.3.2.7. Others
16.8.3.3. India
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Source
16.8.3.3.1. Tobacco,
potato
16.8.3.3.2. Maize
16.8.3.3.3. Nicotiana
benthamiana
16.8.3.3.4. Carrot
cells, tobacco cells
16.8.3.3.5. Strawberry
16.8.3.3.6. Rice
16.8.3.3.7. Lettuce
16.8.3.3.8. Spinach
16.8.3.3.9. Others
16.8.3.4. India
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
16.8.3.4.1. Enterotoxigenic
E. coli
16.8.3.4.2. Ebola
virus
16.8.3.4.2.1. SUDV
16.8.3.4.2.2. ZEBOV
16.8.3.4.2.3. Côte
d’Ivoire ebolavirus
16.8.3.4.2.4. Bundibugyo
ebolavirus
16.8.3.4.3. Norovirus
16.8.3.4.4. Hepatitis
B virus
16.8.3.4.5. Rabies
16.8.3.4.6. Influenza
16.8.3.4.6.1. H1N1
16.8.3.4.6.2. H5N1
16.8.3.4.6.3. H7N9
16.8.3.4.6.4. Others
16.8.3.4.7. Cholera
16.8.3.4.8. Respiratory
Syndromes
16.8.3.4.9. Cancer
16.8.3.4.10. Others
16.8.3.5. India
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Mode of
Administration
16.8.3.5.1. Intramuscular
16.8.3.5.2. Oral
Administration
16.8.3.5.3. Others
16.8.3.6. India
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By End Users
16.8.3.6.1. Hospitals
16.8.3.6.2. Clinics
16.8.3.6.3. Primary
Care Centers
16.8.3.6.4. Others
16.8.4. New
Zealand
16.8.4.1. New
Zealand Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Clinical
Trial
16.8.4.1.1. Phase
I
16.8.4.1.2. Phase
II
16.8.4.1.3. Others
16.8.4.2. New
Zealand Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Type
16.8.4.2.1. Bacterial/
Agrobacterial vaccines
16.8.4.2.2. Transgenic
16.8.4.2.3. Viral
Vaccines
16.8.4.2.4. Fungal
Vaccines
16.8.4.2.5. Recombinant
subunit vaccines
16.8.4.2.6. Parasitic
Vaccines
16.8.4.2.7. Others
16.8.4.3. New
Zealand Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Source
16.8.4.3.1. Tobacco,
potato
16.8.4.3.2. Maize
16.8.4.3.3. Nicotiana
benthamiana
16.8.4.3.4. Carrot
cells, tobacco cells
16.8.4.3.5. Strawberry
16.8.4.3.6. Rice
16.8.4.3.7. Lettuce
16.8.4.3.8. Spinach
16.8.4.3.9. Others
16.8.4.4. New
Zealand Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
16.8.4.4.1. Enterotoxigenic
E. coli
16.8.4.4.2. Ebola
virus
16.8.4.4.2.1. SUDV
16.8.4.4.2.2. ZEBOV
16.8.4.4.2.3. Côte
d’Ivoire ebolavirus
16.8.4.4.2.4. Bundibugyo
ebolavirus
16.8.4.4.3. Norovirus
16.8.4.4.4. Hepatitis
B virus
16.8.4.4.5. Rabies
16.8.4.4.6. Influenza
16.8.4.4.6.1. H1N1
16.8.4.4.6.2. H5N1
16.8.4.4.6.3. H7N9
16.8.4.4.6.4. Others
16.8.4.4.7. Cholera
16.8.4.4.8. Respiratory
Syndromes
16.8.4.4.9. Cancer
16.8.4.4.10. Others
16.8.4.5. New
Zealand Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Mode of
Administration
16.8.4.5.1. Intramuscular
16.8.4.5.2. Oral
Administration
16.8.4.5.3. Others
16.8.4.6. New
Zealand Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By End
Users
16.8.4.6.1. Hospitals
16.8.4.6.2. Clinics
16.8.4.6.3. Primary
Care Centers
16.8.4.6.4. Others
16.8.5. Australia
16.8.5.1. Australia
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Clinical Trial
16.8.5.1.1. Phase
I
16.8.5.1.2. Phase
II
16.8.5.1.3. Others
16.8.5.2. Australia
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Type
16.8.5.2.1. Bacterial/
Agrobacterial vaccines
16.8.5.2.2. Transgenic
16.8.5.2.3. Viral
Vaccines
16.8.5.2.4. Fungal
Vaccines
16.8.5.2.5. Recombinant
subunit vaccines
16.8.5.2.6. Parasitic
Vaccines
16.8.5.2.7. Others
16.8.5.3. Australia
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Source
16.8.5.3.1. Tobacco,
potato
16.8.5.3.2. Maize
16.8.5.3.3. Nicotiana
benthamiana
16.8.5.3.4. Carrot
cells, tobacco cells
16.8.5.3.5. Strawberry
16.8.5.3.6. Rice
16.8.5.3.7. Lettuce
16.8.5.3.8. Spinach
16.8.5.3.9. Others
16.8.5.4. Australia
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
16.8.5.4.1. Enterotoxigenic
E. coli
16.8.5.4.2. Ebola
virus
16.8.5.4.2.1. SUDV
16.8.5.4.2.2. ZEBOV
16.8.5.4.2.3. Côte
d’Ivoire ebolavirus
16.8.5.4.2.4. Bundibugyo
ebolavirus
16.8.5.4.3. Norovirus
16.8.5.4.4. Hepatitis
B virus
16.8.5.4.5. Rabies
16.8.5.4.6. Influenza
16.8.5.4.6.1. H1N1
16.8.5.4.6.2. H5N1
16.8.5.4.6.3. H7N9
16.8.5.4.6.4. Others
16.8.5.4.7. Cholera
16.8.5.4.8. Respiratory
Syndromes
16.8.5.4.9. Cancer
16.8.5.4.10. Others
16.8.5.5. Australia
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Mode of
Administration
16.8.5.5.1. Intramuscular
16.8.5.5.2. Oral
Administration
16.8.5.5.3. Others
16.8.5.6. Australia
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By End Users
16.8.5.6.1. Hospitals
16.8.5.6.2. Clinics
16.8.5.6.3. Primary
Care Centers
16.8.5.6.4. Others
16.8.6. South
Korea
16.8.6.1. South
Korea Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Clinical
Trial
16.8.6.1.1. Phase
I
16.8.6.1.2. Phase
II
16.8.6.1.3. Others
16.8.6.2. South
Korea Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Type
16.8.6.2.1. Bacterial/
Agrobacterial vaccines
16.8.6.2.2. Transgenic
16.8.6.2.3. Viral
Vaccines
16.8.6.2.4. Fungal
Vaccines
16.8.6.2.5. Recombinant
subunit vaccines
16.8.6.2.6. Parasitic
Vaccines
16.8.6.2.7. Others
16.8.6.3. South
Korea Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Source
16.8.6.3.1. Tobacco,
potato
16.8.6.3.2. Maize
16.8.6.3.3. Nicotiana
benthamiana
16.8.6.3.4. Carrot
cells, tobacco cells
16.8.6.3.5. Strawberry
16.8.6.3.6. Rice
16.8.6.3.7. Lettuce
16.8.6.3.8. Spinach
16.8.6.3.9. Others
16.8.6.4. South
Korea Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
16.8.6.4.1. Enterotoxigenic
E. coli
16.8.6.4.2. Ebola
virus
16.8.6.4.2.1. SUDV
16.8.6.4.2.2. ZEBOV
16.8.6.4.2.3. Côte
d’Ivoire ebolavirus
16.8.6.4.2.4. Bundibugyo
ebolavirus
16.8.6.4.3. Norovirus
16.8.6.4.4. Hepatitis
B virus
16.8.6.4.5. Rabies
16.8.6.4.6. Influenza
16.8.6.4.6.1. H1N1
16.8.6.4.6.2. H5N1
16.8.6.4.6.3. H7N9
16.8.6.4.6.4. Others
16.8.6.4.7. Cholera
16.8.6.4.8. Respiratory
Syndromes
16.8.6.4.9. Cancer
16.8.6.4.10. Others
16.8.6.5. South
Korea Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Mode of
Administration
16.8.6.5.1. Intramuscular
16.8.6.5.2. Oral
Administration
16.8.6.5.3. Others
16.8.6.6. South
Korea Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By End Users
16.8.6.6.1. Hospitals
16.8.6.6.2. Clinics
16.8.6.6.3. Primary
Care Centers
16.8.6.6.4. Others
16.8.7. Southeast
Asia
16.8.7.1. Southeast
Asia Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Clinical
Trial
16.8.7.1.1. Phase
I
16.8.7.1.2. Phase
II
16.8.7.1.3. Others
16.8.7.2. Southeast
Asia Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Type
16.8.7.2.1. Bacterial/
Agrobacterial vaccines
16.8.7.2.2. Transgenic
16.8.7.2.3. Viral
Vaccines
16.8.7.2.4. Fungal
Vaccines
16.8.7.2.5. Recombinant
subunit vaccines
16.8.7.2.6. Parasitic
Vaccines
16.8.7.2.7. Others
16.8.7.3. Southeast
Asia Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Source
16.8.7.3.1. Tobacco,
potato
16.8.7.3.2. Maize
16.8.7.3.3. Nicotiana
benthamiana
16.8.7.3.4. Carrot
cells, tobacco cells
16.8.7.3.5. Strawberry
16.8.7.3.6. Rice
16.8.7.3.7. Lettuce
16.8.7.3.8. Spinach
16.8.7.3.9. Others
16.8.7.4. Southeast
Asia Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
16.8.7.4.1. Enterotoxigenic
E. coli
16.8.7.4.2. Ebola
virus
16.8.7.4.2.1. SUDV
16.8.7.4.2.2. ZEBOV
16.8.7.4.2.3. Côte
d’Ivoire ebolavirus
16.8.7.4.2.4. Bundibugyo
ebolavirus
16.8.7.4.3. Norovirus
16.8.7.4.4. Hepatitis
B virus
16.8.7.4.5. Rabies
16.8.7.4.6. Influenza
16.8.7.4.6.1. H1N1
16.8.7.4.6.2. H5N1
16.8.7.4.6.3. H7N9
16.8.7.4.6.4. Others
16.8.7.4.7. Cholera
16.8.7.4.8. Respiratory
Syndromes
16.8.7.4.9. Cancer
16.8.7.4.10. Others
16.8.7.5. Southeast
Asia Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Mode of
Administration
16.8.7.5.1. Intramuscular
16.8.7.5.2. Oral
Administration
16.8.7.5.3. Others
16.8.7.6. Southeast
Asia Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By End Users
16.8.7.6.1. Hospitals
16.8.7.6.2. Clinics
16.8.7.6.3. Primary
Care Centers
16.8.7.6.4. Others
16.8.7.7. Southeast
Asia Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Country
16.8.7.7.1. Indonesia
16.8.7.7.2. Thailand
16.8.7.7.3. Malaysia
16.8.7.7.4. Singapore
16.8.7.7.5. Rest
of Southeast Asia
16.8.8. Rest of
Asia Pacific
16.8.8.1. Rest
of Asia Pacific Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By
Clinical Trial
16.8.8.1.1. Phase
I
16.8.8.1.2. Phase
II
16.8.8.1.3. Others
16.8.8.2. Rest
of Asia Pacific Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By
Type
16.8.8.2.1. Bacterial/
Agrobacterial vaccines
16.8.8.2.2. Transgenic
16.8.8.2.3. Viral
Vaccines
16.8.8.2.4. Fungal
Vaccines
16.8.8.2.5. Recombinant
subunit vaccines
16.8.8.2.6. Parasitic
Vaccines
16.8.8.2.7. Others
16.8.8.3. Rest
of Asia Pacific Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By
Source
16.8.8.3.1. Tobacco,
potato
16.8.8.3.2. Maize
16.8.8.3.3. Nicotiana
benthamiana
16.8.8.3.4. Carrot
cells, tobacco cells
16.8.8.3.5. Strawberry
16.8.8.3.6. Rice
16.8.8.3.7. Lettuce
16.8.8.3.8. Spinach
16.8.8.3.9. Others
16.8.8.4. Rest
of Asia Pacific Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By
Disease Indication
16.8.8.4.1. Enterotoxigenic
E. coli
16.8.8.4.2. Ebola
virus
16.8.8.4.2.1. SUDV
16.8.8.4.2.2. ZEBOV
16.8.8.4.2.3. Côte
d’Ivoire ebolavirus
16.8.8.4.2.4. Bundibugyo
ebolavirus
16.8.8.4.3. Norovirus
16.8.8.4.4. Hepatitis
B virus
16.8.8.4.5. Rabies
16.8.8.4.6. Influenza
16.8.8.4.6.1. H1N1
16.8.8.4.6.2. H5N1
16.8.8.4.6.3. H7N9
16.8.8.4.6.4. Others
16.8.8.4.7. Cholera
16.8.8.4.8. Respiratory
Syndromes
16.8.8.4.9. Cancer
16.8.8.4.10. Others
16.8.8.5. Rest
of Asia Pacific Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By
Mode of Administration
16.8.8.5.1. Intramuscular
16.8.8.5.2. Oral
Administration
16.8.8.5.3. Others
16.8.8.6. Rest
of Asia Pacific Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By
End Users
16.8.8.6.1. Hospitals
16.8.8.6.2. Clinics
16.8.8.6.3. Primary
Care Centers
16.8.8.6.4. Others
16.9. Key
Segment for Channeling Investments
16.9.1. By
Country
16.9.2. By
Clinical Trial
16.9.3. By Type
16.9.4. By
Source
16.9.5. By
Disease Indication
16.9.6. By Mode
of Administration
16.9.7. By End
Users
17. Middle East and Africa Plant-based Vaccines Market Analysis
and Forecasts, 2020 - 2028
17.1. Overview
17.1.1. Middle
East and Africa Plant-based Vaccines Market Revenue (US$ Mn)
17.2. Middle
East and Africa Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By
Clinical Trial
17.2.1. Phase I
17.2.2. Phase
II
17.2.3. Others
17.3. Middle
East and Africa Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By
Type
17.3.1. Bacterial/
Agrobacterial vaccines
17.3.2. Transgenic
17.3.3. Viral
Vaccines
17.3.4. Fungal
Vaccines
17.3.5. Recombinant
subunit vaccines
17.3.6. Parasitic
Vaccines
17.3.7. Others
17.4. Middle
East and Africa Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By
Source
17.4.1. Tobacco,
potato
17.4.2. Maize
17.4.3. Nicotiana
benthamiana
17.4.4. Carrot
cells, tobacco cells
17.4.5. Strawberry
17.4.6. Rice
17.4.7. Lettuce
17.4.8. Spinach
17.4.9. Others
17.5. Middle
East and Africa Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By
Disease Indication
17.5.1. Enterotoxigenic
E. coli
17.5.2. Ebola
virus
17.5.2.1. SUDV
17.5.2.2. ZEBOV
17.5.2.3. Côte
d’Ivoire ebolavirus
17.5.2.4. Bundibugyo
ebolavirus
17.5.3. Norovirus
17.5.4. Hepatitis
B virus
17.5.5. Rabies
17.5.6. Influenza
17.5.6.1. H1N1
17.5.6.2. H5N1
17.5.6.3. H7N9
17.5.6.4. Others
17.5.7. Cholera
17.5.8. Respiratory
Syndromes
17.5.9. Cancer
17.5.10. Others
17.6. Middle
East and Africa Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By
Mode of Administration
17.6.1. Intramuscular
17.6.2. Oral
Administration
17.6.3. Others
17.7. Middle
East and Africa Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By
End Users
17.7.1. Hospitals
17.7.2. Clinics
17.7.3. Primary
Care Centers
17.7.4. Others
17.8. Middle
East and Africa Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By
Country
17.8.1. Saudi
Arabia
17.8.1.1. Saudi
Arabia Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Clinical
Trial
17.8.1.1.1. Phase
I
17.8.1.1.2. Phase
II
17.8.1.1.3. Others
17.8.1.2. Saudi
Arabia Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Type
17.8.1.2.1. Bacterial/
Agrobacterial vaccines
17.8.1.2.2. Transgenic
17.8.1.2.3. Viral
Vaccines
17.8.1.2.4. Fungal
Vaccines
17.8.1.2.5. Recombinant
subunit vaccines
17.8.1.2.6. Parasitic
Vaccines
17.8.1.2.7. Others
17.8.1.3. Saudi
Arabia Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Source
17.8.1.3.1. Tobacco,
potato
17.8.1.3.2. Maize
17.8.1.3.3. Nicotiana
benthamiana
17.8.1.3.4. Carrot
cells, tobacco cells
17.8.1.3.5. Strawberry
17.8.1.3.6. Rice
17.8.1.3.7. Lettuce
17.8.1.3.8. Spinach
17.8.1.3.9. Others
17.8.1.4. Saudi
Arabia Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
17.8.1.4.1. Enterotoxigenic
E. coli
17.8.1.4.2. Ebola
virus
17.8.1.4.2.1. SUDV
17.8.1.4.2.2. ZEBOV
17.8.1.4.2.3. Côte
d’Ivoire ebolavirus
17.8.1.4.2.4. Bundibugyo
ebolavirus
17.8.1.4.3. Norovirus
17.8.1.4.4. Hepatitis
B virus
17.8.1.4.5. Rabies
17.8.1.4.6. Influenza
17.8.1.4.6.1. H1N1
17.8.1.4.6.2. H5N1
17.8.1.4.6.3. H7N9
17.8.1.4.6.4. Others
17.8.1.4.7. Cholera
17.8.1.4.8. Respiratory
Syndromes
17.8.1.4.9. Cancer
17.8.1.4.10. Others
17.8.1.5. Saudi
Arabia Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Mode of
Administration
17.8.1.5.1. Intramuscular
17.8.1.5.2. Oral
Administration
17.8.1.5.3. Others
17.8.1.6. Saudi
Arabia Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By End Users
17.8.1.6.1. Hospitals
17.8.1.6.2. Clinics
17.8.1.6.3. Primary
Care Centers
17.8.1.6.4. Others
17.8.2. UAE
17.8.2.1. UAE
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Clinical Trial
17.8.2.1.1. Phase
I
17.8.2.1.2. Phase
II
17.8.2.1.3. Others
17.8.2.2. UAE
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Type
17.8.2.2.1. Bacterial/
Agrobacterial vaccines
17.8.2.2.2. Transgenic
17.8.2.2.3. Viral
Vaccines
17.8.2.2.4. Fungal
Vaccines
17.8.2.2.5. Recombinant
subunit vaccines
17.8.2.2.6. Parasitic
Vaccines
17.8.2.2.7. Others
17.8.2.3. UAE
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Source
17.8.2.3.1. Tobacco,
potato
17.8.2.3.2. Maize
17.8.2.3.3. Nicotiana
benthamiana
17.8.2.3.4. Carrot
cells, tobacco cells
17.8.2.3.5. Strawberry
17.8.2.3.6. Rice
17.8.2.3.7. Lettuce
17.8.2.3.8. Spinach
17.8.2.3.9. Others
17.8.2.4. UAE
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
17.8.2.4.1. Enterotoxigenic
E. coli
17.8.2.4.2. Ebola
virus
17.8.2.4.2.1. SUDV
17.8.2.4.2.2. ZEBOV
17.8.2.4.2.3. Côte
d’Ivoire ebolavirus
17.8.2.4.2.4. Bundibugyo
ebolavirus
17.8.2.4.3. Norovirus
17.8.2.4.4. Hepatitis
B virus
17.8.2.4.5. Rabies
17.8.2.4.6. Influenza
17.8.2.4.6.1. H1N1
17.8.2.4.6.2. H5N1
17.8.2.4.6.3. H7N9
17.8.2.4.6.4. Others
17.8.2.4.7. Cholera
17.8.2.4.8. Respiratory
Syndromes
17.8.2.4.9. Cancer
17.8.2.4.10. Others
17.8.2.5. UAE
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Mode of
Administration
17.8.2.5.1. Intramuscular
17.8.2.5.2. Oral
Administration
17.8.2.5.3. Others
17.8.2.6. UAE
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By End Users
17.8.2.6.1. Hospitals
17.8.2.6.2. Clinics
17.8.2.6.3. Primary
Care Centers
17.8.2.6.4. Others
17.8.3. Egypt
17.8.3.1. Egypt
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Clinical Trial
17.8.3.1.1. Phase
I
17.8.3.1.2. Phase
II
17.8.3.1.3. Others
17.8.3.2. Egypt
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Type
17.8.3.2.1. Bacterial/
Agrobacterial vaccines
17.8.3.2.2. Transgenic
17.8.3.2.3. Viral
Vaccines
17.8.3.2.4. Fungal
Vaccines
17.8.3.2.5. Recombinant
subunit vaccines
17.8.3.2.6. Parasitic
Vaccines
17.8.3.2.7. Others
17.8.3.3. Egypt
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Source
17.8.3.3.1. Tobacco,
potato
17.8.3.3.2. Maize
17.8.3.3.3. Nicotiana
benthamiana
17.8.3.3.4. Carrot
cells, tobacco cells
17.8.3.3.5. Strawberry
17.8.3.3.6. Rice
17.8.3.3.7. Lettuce
17.8.3.3.8. Spinach
17.8.3.3.9. Others
17.8.3.4. Egypt
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
17.8.3.4.1. Enterotoxigenic
E. coli
17.8.3.4.2. Ebola
virus
17.8.3.4.2.1. SUDV
17.8.3.4.2.2. ZEBOV
17.8.3.4.2.3. Côte
d’Ivoire ebolavirus
17.8.3.4.2.4. Bundibugyo
ebolavirus
17.8.3.4.3. Norovirus
17.8.3.4.4. Hepatitis
B virus
17.8.3.4.5. Rabies
17.8.3.4.6. Influenza
17.8.3.4.6.1. H1N1
17.8.3.4.6.2. H5N1
17.8.3.4.6.3. H7N9
17.8.3.4.6.4. Others
17.8.3.4.7. Cholera
17.8.3.4.8. Respiratory
Syndromes
17.8.3.4.9. Cancer
17.8.3.4.10. Others
17.8.3.5. Egypt
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Mode of
Administration
17.8.3.5.1. Intramuscular
17.8.3.5.2. Oral
Administration
17.8.3.5.3. Others
17.8.3.6. Egypt
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By End Users
17.8.3.6.1. Hospitals
17.8.3.6.2. Clinics
17.8.3.6.3. Primary
Care Centers
17.8.3.6.4. Others
17.8.4. Kuwait
17.8.4.1. Kuwait
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Clinical Trial
17.8.4.1.1. Phase
I
17.8.4.1.2. Phase
II
17.8.4.1.3. Others
17.8.4.2. Kuwait
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Type
17.8.4.2.1. Bacterial/
Agrobacterial vaccines
17.8.4.2.2. Transgenic
17.8.4.2.3. Viral
Vaccines
17.8.4.2.4. Fungal
Vaccines
17.8.4.2.5. Recombinant
subunit vaccines
17.8.4.2.6. Parasitic
Vaccines
17.8.4.2.7. Others
17.8.4.3. Kuwait
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Source
17.8.4.3.1. Tobacco,
potato
17.8.4.3.2. Maize
17.8.4.3.3. Nicotiana
benthamiana
17.8.4.3.4. Carrot
cells, tobacco cells
17.8.4.3.5. Strawberry
17.8.4.3.6. Rice
17.8.4.3.7. Lettuce
17.8.4.3.8. Spinach
17.8.4.3.9. Others
17.8.4.4. Kuwait
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
17.8.4.4.1. Enterotoxigenic
E. coli
17.8.4.4.2. Ebola
virus
17.8.4.4.2.1. SUDV
17.8.4.4.2.2. ZEBOV
17.8.4.4.2.3. Côte
d’Ivoire ebolavirus
17.8.4.4.2.4. Bundibugyo
ebolavirus
17.8.4.4.3. Norovirus
17.8.4.4.4. Hepatitis
B virus
17.8.4.4.5. Rabies
17.8.4.4.6. Influenza
17.8.4.4.6.1. H1N1
17.8.4.4.6.2. H5N1
17.8.4.4.6.3. H7N9
17.8.4.4.6.4. Others
17.8.4.4.7. Cholera
17.8.4.4.8. Respiratory
Syndromes
17.8.4.4.9. Cancer
17.8.4.4.10. Others
17.8.4.5. Kuwait
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Mode of Administration
17.8.4.5.1. Intramuscular
17.8.4.5.2. Oral
Administration
17.8.4.5.3. Others
17.8.4.6. Kuwait
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By End Users
17.8.4.6.1. Hospitals
17.8.4.6.2. Clinics
17.8.4.6.3. Primary
Care Centers
17.8.4.6.4. Others
17.8.5. South
Africa
17.8.5.1. South
Africa Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Clinical
Trial
17.8.5.1.1. Phase
I
17.8.5.1.2. Phase
II
17.8.5.1.3. Others
17.8.5.2. South
Africa Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Type
17.8.5.2.1. Bacterial/
Agrobacterial vaccines
17.8.5.2.2. Transgenic
17.8.5.2.3. Viral
Vaccines
17.8.5.2.4. Fungal
Vaccines
17.8.5.2.5. Recombinant
subunit vaccines
17.8.5.2.6. Parasitic
Vaccines
17.8.5.2.7. Others
17.8.5.3. South
Africa Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Source
17.8.5.3.1. Tobacco,
potato
17.8.5.3.2. Maize
17.8.5.3.3. Nicotiana
benthamiana
17.8.5.3.4. Carrot
cells, tobacco cells
17.8.5.3.5. Strawberry
17.8.5.3.6. Rice
17.8.5.3.7. Lettuce
17.8.5.3.8. Spinach
17.8.5.3.9. Others
17.8.5.4. South
Africa Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
17.8.5.4.1. Enterotoxigenic
E. coli
17.8.5.4.2. Ebola
virus
17.8.5.4.2.1. SUDV
17.8.5.4.2.2. ZEBOV
17.8.5.4.2.3. Côte
d’Ivoire ebolavirus
17.8.5.4.2.4. Bundibugyo
ebolavirus
17.8.5.4.3. Norovirus
17.8.5.4.4. Hepatitis
B virus
17.8.5.4.5. Rabies
17.8.5.4.6. Influenza
17.8.5.4.6.1. H1N1
17.8.5.4.6.2. H5N1
17.8.5.4.6.3. H7N9
17.8.5.4.6.4. Others
17.8.5.4.7. Cholera
17.8.5.4.8. Respiratory
Syndromes
17.8.5.4.9. Cancer
17.8.5.4.10. Others
17.8.5.5. South
Africa Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Mode of
Administration
17.8.5.5.1. Intramuscular
17.8.5.5.2. Oral
Administration
17.8.5.5.3. Others
17.8.5.6. South
Africa Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By End Users
17.8.5.6.1. Hospitals
17.8.5.6.2. Clinics
17.8.5.6.3. Primary
Care Centers
17.8.5.6.4. Others
17.8.6. Rest of
Middle East & Africa
17.8.6.1. Rest
of Middle East & Africa Plant-based Vaccines Market Revenue (US$ Mn) and
Forecasts, By Clinical Trial
17.8.6.1.1. Phase
I
17.8.6.1.2. Phase
II
17.8.6.1.3. Others
17.8.6.2. Rest
of Middle East & Africa Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts,
By Type
17.8.6.2.1. Bacterial/
Agrobacterial vaccines
17.8.6.2.2. Transgenic
17.8.6.2.3. Viral
Vaccines
17.8.6.2.4. Fungal
Vaccines
17.8.6.2.5. Recombinant
subunit vaccines
17.8.6.2.6. Parasitic
Vaccines
17.8.6.2.7. Others
17.8.6.3. Rest
of Middle East & Africa Plant-based Vaccines Market Revenue (US$ Mn) and
Forecasts, By Source
17.8.6.3.1. Tobacco,
potato
17.8.6.3.2. Maize
17.8.6.3.3. Nicotiana
benthamiana
17.8.6.3.4. Carrot
cells, tobacco cells
17.8.6.3.5. Strawberry
17.8.6.3.6. Rice
17.8.6.3.7. Lettuce
17.8.6.3.8. Spinach
17.8.6.3.9. Others
17.8.6.4. Rest
of Middle East & Africa Plant-based Vaccines Market Revenue (US$ Mn) and
Forecasts, By Disease Indication
17.8.6.4.1. Enterotoxigenic
E. coli
17.8.6.4.2. Ebola
virus
17.8.6.4.2.1. SUDV
17.8.6.4.2.2. ZEBOV
17.8.6.4.2.3. Côte
d’Ivoire ebolavirus
17.8.6.4.2.4. Bundibugyo
ebolavirus
17.8.6.4.3. Norovirus
17.8.6.4.4. Hepatitis
B virus
17.8.6.4.5. Rabies
17.8.6.4.6. Influenza
17.8.6.4.6.1. H1N1
17.8.6.4.6.2. H5N1
17.8.6.4.6.3. H7N9
17.8.6.4.6.4. Others
17.8.6.4.7. Cholera
17.8.6.4.8. Respiratory
Syndromes
17.8.6.4.9. Cancer
17.8.6.4.10. Others
17.8.6.5. Rest
of Middle East & Africa Plant-based Vaccines Market Revenue (US$ Mn) and
Forecasts, By Mode of Administration
17.8.6.5.1. Intramuscular
17.8.6.5.2. Oral
Administration
17.8.6.5.3. Others
17.8.6.6. Rest
of Middle East & Africa Plant-based Vaccines Market Revenue (US$ Mn) and
Forecasts, By End Users
17.8.6.6.1. Hospitals
17.8.6.6.2. Clinics
17.8.6.6.3. Primary
Care Centers
17.8.6.6.4. Others
17.9. Key
Segment for Channeling Investments
17.9.1. By Country
17.9.2. By
Clinical Trial
17.9.3. By Type
17.9.4. By
Source
17.9.5. By
Disease Indication
17.9.6. By Mode
of Administration
17.9.7. By End
Users
18. Latin America Plant-based Vaccines Market Analysis and
Forecasts, 2020 - 2028
18.1. Overview
18.1.1. Latin
America Plant-based Vaccines Market Revenue (US$ Mn)
18.2. Latin
America Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Clinical
Trial
18.2.1. Phase I
18.2.2. Phase
II
18.2.3. Others
18.3. Latin
America Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Type
18.3.1. Bacterial/
Agrobacterial vaccines
18.3.2. Transgenic
18.3.3. Viral
Vaccines
18.3.4. Fungal
Vaccines
18.3.5. Recombinant
subunit vaccines
18.3.6. Parasitic
Vaccines
18.3.7. Others
18.4. Latin
America Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Source
18.4.1. Tobacco,
potato
18.4.2. Maize
18.4.3. Nicotiana
benthamiana
18.4.4. Carrot
cells, tobacco cells
18.4.5. Strawberry
18.4.6. Rice
18.4.7. Lettuce
18.4.8. Spinach
18.4.9. Others
18.5. Latin
America Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
18.5.1. Enterotoxigenic
E. coli
18.5.2. Ebola
virus
18.5.2.1. SUDV
18.5.2.2. ZEBOV
18.5.2.3. Côte
d’Ivoire ebolavirus
18.5.2.4. Bundibugyo
ebolavirus
18.5.3. Norovirus
18.5.4. Hepatitis
B virus
18.5.5. Rabies
18.5.6. Influenza
18.5.6.1. H1N1
18.5.6.2. H5N1
18.5.6.3. H7N9
18.5.6.4. Others
18.5.7. Cholera
18.5.8. Respiratory
Syndromes
18.5.9. Cancer
18.5.10. Others
18.6. Latin
America Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Mode of
Administration
18.6.1. Intramuscular
18.6.2. Oral
Administration
18.6.3. Others
18.7. Latin
America Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By End
Users
18.7.1. Hospitals
18.7.2. Clinics
18.7.3. Primary
Care Centers
18.7.4. Others
18.8. Latin
America Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Country
18.8.1. Brazil
18.8.1.1. Brazil
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Clinical Trial
18.8.1.1.1. Phase
I
18.8.1.1.2. Phase
II
18.8.1.1.3. Others
18.8.1.2. Brazil
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Type
18.8.1.2.1. Bacterial/
Agrobacterial vaccines
18.8.1.2.2. Transgenic
18.8.1.2.3. Viral
Vaccines
18.8.1.2.4. Fungal
Vaccines
18.8.1.2.5. Recombinant
subunit vaccines
18.8.1.2.6. Parasitic
Vaccines
18.8.1.2.7. Others
18.8.1.3. Brazil
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Source
18.8.1.3.1. Tobacco,
potato
18.8.1.3.2. Maize
18.8.1.3.3. Nicotiana
benthamiana
18.8.1.3.4. Carrot
cells, tobacco cells
18.8.1.3.5. Strawberry
18.8.1.3.6. Rice
18.8.1.3.7. Lettuce
18.8.1.3.8. Spinach
18.8.1.3.9. Others
18.8.1.4. Brazil
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
18.8.1.4.1. Enterotoxigenic
E. coli
18.8.1.4.2. Ebola
virus
18.8.1.4.2.1. SUDV
18.8.1.4.2.2. ZEBOV
18.8.1.4.2.3. Côte
d’Ivoire ebolavirus
18.8.1.4.2.4. Bundibugyo
ebolavirus
18.8.1.4.3. Norovirus
18.8.1.4.4. Hepatitis
B virus
18.8.1.4.5. Rabies
18.8.1.4.6. Influenza
18.8.1.4.6.1. H1N1
18.8.1.4.6.2. H5N1
18.8.1.4.6.3. H7N9
18.8.1.4.6.4. Others
18.8.1.4.7. Cholera
18.8.1.4.8. Respiratory
Syndromes
18.8.1.4.9. Cancer
18.8.1.4.10. Others
18.8.1.5. Brazil
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Mode of
Administration
18.8.1.5.1. Intramuscular
18.8.1.5.2. Oral
Administration
18.8.1.5.3. Others
18.8.1.6. Brazil
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By End Users
18.8.1.6.1. Hospitals
18.8.1.6.2. Clinics
18.8.1.6.3. Primary
Care Centers
18.8.1.6.4. Others
18.8.2. Argentina
18.8.2.1. Argentina
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Clinical Trial
18.8.2.1.1. Phase
I
18.8.2.1.2. Phase
II
18.8.2.1.3. Others
18.8.2.2. Argentina
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Type
18.8.2.2.1. Bacterial/
Agrobacterial vaccines
18.8.2.2.2. Transgenic
18.8.2.2.3. Viral
Vaccines
18.8.2.2.4. Fungal
Vaccines
18.8.2.2.5. Recombinant
subunit vaccines
18.8.2.2.6. Parasitic
Vaccines
18.8.2.2.7. Others
18.8.2.3. Argentina
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Source
18.8.2.3.1. Tobacco,
potato
18.8.2.3.2. Maize
18.8.2.3.3. Nicotiana
benthamiana
18.8.2.3.4. Carrot
cells, tobacco cells
18.8.2.3.5. Strawberry
18.8.2.3.6. Rice
18.8.2.3.7. Lettuce
18.8.2.3.8. Spinach
18.8.2.3.9. Others
18.8.2.4. Argentina
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
18.8.2.4.1. Enterotoxigenic
E. coli
18.8.2.4.2. Ebola
virus
18.8.2.4.2.1. SUDV
18.8.2.4.2.2. ZEBOV
18.8.2.4.2.3. Côte
d’Ivoire ebolavirus
18.8.2.4.2.4. Bundibugyo
ebolavirus
18.8.2.4.3. Norovirus
18.8.2.4.4. Hepatitis
B virus
18.8.2.4.5. Rabies
18.8.2.4.6. Influenza
18.8.2.4.6.1. H1N1
18.8.2.4.6.2. H5N1
18.8.2.4.6.3. H7N9
18.8.2.4.6.4. Others
18.8.2.4.7. Cholera
18.8.2.4.8. Respiratory
Syndromes
18.8.2.4.9. Cancer
18.8.2.4.10. Others
18.8.2.5. Argentina
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By Mode of
Administration
18.8.2.5.1. Intramuscular
18.8.2.5.2. Oral
Administration
18.8.2.5.3. Others
18.8.2.6. Argentina
Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By End Users
18.8.2.6.1. Hospitals
18.8.2.6.2. Clinics
18.8.2.6.3. Primary
Care Centers
18.8.2.6.4. Others
18.8.3. Rest of
Latin America
18.8.3.1. Rest
of Latin America Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By
Clinical Trial
18.8.3.1.1. Phase
I
18.8.3.1.2. Phase
II
18.8.3.1.3. Others
18.8.3.2. Rest
of Latin America Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By
Type
18.8.3.2.1. Bacterial/
Agrobacterial vaccines
18.8.3.2.2. Transgenic
18.8.3.2.3. Viral
Vaccines
18.8.3.2.4. Fungal
Vaccines
18.8.3.2.5. Recombinant
subunit vaccines
18.8.3.2.6. Parasitic
Vaccines
18.8.3.2.7. Others
18.8.3.3. Rest
of Latin America Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By
Source
18.8.3.3.1. Tobacco,
potato
18.8.3.3.2. Maize
18.8.3.3.3. Nicotiana
benthamiana
18.8.3.3.4. Carrot
cells, tobacco cells
18.8.3.3.5. Strawberry
18.8.3.3.6. Rice
18.8.3.3.7. Lettuce
18.8.3.3.8. Spinach
18.8.3.3.9. Others
18.8.3.4. Rest
of Latin America Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By
Disease Indication
18.8.3.4.1. Enterotoxigenic
E. coli
18.8.3.4.2. Ebola
virus
18.8.3.4.2.1. SUDV
18.8.3.4.2.2. ZEBOV
18.8.3.4.2.3. Côte
d’Ivoire ebolavirus
18.8.3.4.2.4. Bundibugyo
ebolavirus
18.8.3.4.3. Norovirus
18.8.3.4.4. Hepatitis
B virus
18.8.3.4.5. Rabies
18.8.3.4.6. Influenza
18.8.3.4.6.1. H1N1
18.8.3.4.6.2. H5N1
18.8.3.4.6.3. H7N9
18.8.3.4.6.4. Others
18.8.3.4.7. Cholera
18.8.3.4.8. Respiratory
Syndromes
18.8.3.4.9. Cancer
18.8.3.4.10. Others
18.8.3.5. Rest
of Latin America Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By
Mode of Administration
18.8.3.5.1. Intramuscular
18.8.3.5.2. Oral
Administration
18.8.3.5.3. Others
18.8.3.6. Rest
of Latin America Plant-based Vaccines Market Revenue (US$ Mn) and Forecasts, By
End Users
18.8.3.6.1. Hospitals
18.8.3.6.2. Clinics
18.8.3.6.3. Primary
Care Centers
18.8.3.6.4. Others
18.9. Key
Segment for Channeling Investments
18.9.1. By
Country
18.9.2. By
Clinical Trial
18.9.3. By Type
18.9.4. By
Source
18.9.5. By Disease
Indication
18.9.6. By Mode
of Administration
18.9.7. By End
Users
19. Competitive Benchmarking
19.1. Market
Share Analysis, 2019
19.2. Global
Presence and Growth Strategies
19.2.1. Mergers
and Acquisitions
19.2.2. Product
Launches
19.2.3. Investments
Trends
19.2.4. R&D
Initiatives
20. Player Profiles
20.1. Creative Biolabs
20.1.1. Company
Details
20.1.2. Company
Overview
20.1.3. Product
Offerings
20.1.4. Key
Developments
20.1.5. Financial
Analysis
20.1.6. SWOT
Analysis
20.1.7. Business
Strategies
20.2. iBio,
Inc.
20.2.1. Company
Details
20.2.2. Company
Overview
20.2.3. Product
Offerings
20.2.4. Key
Developments
20.2.5. Financial
Analysis
20.2.6. SWOT
Analysis
20.2.7. Business
Strategies
20.3. Medicago
Inc.
20.3.1. Company
Details
20.3.2. Company
Overview
20.3.3. Product
Offerings
20.3.4. Key
Developments
20.3.5. Financial
Analysis
20.3.6. SWOT
Analysis
20.3.7. Business
Strategies
20.4. Nomad
Bioscience GmbH (Icon Genetics GmbH)
20.4.1. Company
Details
20.4.2. Company
Overview
20.4.3. Product
Offerings
20.4.4. Key
Developments
20.4.5. Financial
Analysis
20.4.6. SWOT
Analysis
20.4.7. Business Strategies
20.5. Other
Industry Participants
21. Key Findings
Note: This ToC is tentative
and can be changed according to the research study conducted during the course
of report completion.
**Exclusive for Multi-User and
Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
Reach to us
Call us on
+91-74002-42424
Drop us an email at
sales@absolutemarketsinsights.com
Why Absolute Markets Insights?
An effective strategy is the entity that influences a business to stand out of the crowd. An organization with a phenomenal strategy for success dependably has the edge over the rivals in the market. It offers the organizations a head start in planning their strategy. Absolute Market Insights is the new initiation in the industry that will furnish you with the lead your business needs. Absolute Market Insights is the best destination for your business intelligence and analytical solutions; essentially because our qualitative and quantitative sources of information are competent to give one-stop solutions. We inventively combine qualitative and quantitative research in accurate proportions to have the best report, which not only gives the most recent insights but also assists you to grow.